Selective glycosidase inhibitors and uses thereof

ABSTRACT

The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

FIELD OF THE INVENTION

This application relates to compounds which selectively inhibit glycosidases and uses thereof.

BACKGROUND OF THE INVENTION

A wide range of cellular proteins, both nuclear and cytoplasmic, are post-translationally modified by the addition of the monosaccharide 2-acetamido-2-deoxy-β-D-glucopyranoside (β-N-acetylglucosamine) which is attached via an β-glycosidic linkage.¹ This modification is generally referred to as O-linked N-acetylglucosamine or O-GlcNAc. The enzyme responsible for post-translationally linking β-N-acetylglucosamine (GlcNAc) to specific serine and threonine residues of numerous nucleocytoplasmic proteins is O-GlcNAc transferase (OGT).²⁻⁵ A second enzyme, known as glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase)^(6,7) removes this post-translational modification to liberate proteins making the O-GlcNAc-modification a dynamic cycle occurring several times during the lifetime of a protein.⁸

O-GlcNAc-modified proteins regulate a wide range of vital cellular functions including, for example, transcription,^(9,12) proteasomal degradation,¹³ and cellular signaling.¹⁴ O-GlcNAc is also found on many structural proteins.^(15,17) For example, it has been found on a number of cytoskeletal proteins, including neurofilament proteins,^(18,19) synapsins,^(6,20) synapsin-specific clathrin assembly protein AP-3,⁷ and ankyrinG.¹⁴ O-GlcNAc modification has been found to be abundant in the brain.^(21,22) It has also been found on proteins clearly implicated in the etiology of several diseases including Alzheimer's disease (AD) and cancer.

For example, it is well established that AD and a number of related tauopathies including Downs' syndrome, Pick's disease, Niemann-Pick Type C disease, and amyotrophic lateral sclerosis (ALS) are characterized, in part, by the development of neurofibrillary tangles (NFTs). These NFTs are aggregates of paired helical filaments (PHFs) and are composed of an abnormal form of the cytoskeletal protein “tau”. Normally tau stabilizes a key cellular network of microtubules that is essential for distributing proteins and nutrients within neurons. In AD patients, however, tau becomes hyperphosphorylated, disrupting its normal functions, forming PHFs and ultimately aggregating to form NFTs. Six isoforms of tau are found in the human brain. In AD patients, all six isoforms of tau are found in NFTs, and all are markedly hyperphosphorylated.^(23,24) Tau in healthy brain tissue bears only 2 or 3 phosphate groups, whereas those found in the brains of AD patients bear, on average, 8 phosphate groups.^(25,26) A clear parallel between NFT levels in the brains of AD patients and the severity of dementia strongly supports a key role for tau dysfunction in AD.^(27,29) The precise causes of this hyperphosphorylation of tau remain elusive. Accordingly, considerable effort has been dedicated toward: a) elucidating the molecular physiological basis of tau hyperphosphorylation;³⁰ and b) identifying strategies that could limit tau hyperphosphorylation in the hope that these might halt, or even reverse, the progression of Alzheimer's disease³¹⁻³⁴ Thus far, several lines of evidence suggest that up-regulation of a number of kinases may be involved in hyperphosphorylation of tau,^(21,35,36) although very recently, an alternative basis for this hyperphosphorylation has been advanced.²¹

In particular, it has emerged that phosphate levels of tau are regulated by the levels of O-GlcNAc on tau. The presence of O-GlcNAc on tau has stimulated studies that correlate O-GlcNAc levels with tau phosphorylation levels. The interest in this field stems from the observation that O-GlcNAc modification has been found to occur on many proteins at amino acid residues that are also known to be phosphorylated.³⁷⁻³⁹ Consistent with this observation, it has been found that increases in phosphorylation levels result in decreased O-GlcNAc levels and conversely, increased O-GlcNAc levels correlate with decreased phosphorylation levels.⁴⁰ This reciprocal relationship between O-GlcNAc and phosphorylation has been termed the “Yin-Yang hypothesis”⁴¹ and has gained strong biochemical support by the discovery that the enzyme OGT⁴ forms a functional complex with phosphatases that act to remove phosphate groups from proteins.⁴² Like phosphorylation, O-GlcNAc is a dynamic modification that can be removed and reinstalled several times during the lifespan of a protein. Suggestively, the gene encoding O-GlcNAcase has been mapped to a chromosomal locus that is linked to AD.^(7,43) Hyperphosphorylated tau in human AD brains has markedly lower levels of O-GlcNAc than are found in healthy human brains.²¹ It has been shown that O-GlcNAc levels of soluble tau protein from human brains affected with AD are markedly lower than those from healthy brain.²¹ Furthermore, PHF from diseased brain was suggested to lack completely any O-GlcNAc modification whatsoever.²¹ The molecular basis of this hypoglycosylation of tau is not known, although it may stem from increased activity of kinases and/or dysfunction of one of the enzymes involved in processing O-GlcNAc. Supporting this latter view, in both PC-12 neuronal cells and in brain tissue sections from mice, a nonselective N-acetylglucosamindase inhibitor was used to increase tau O-GlcNAc levels, whereupon it was observed that phosphorylation levels decreased.²¹ The implication of these collective results is that by maintaining healthy O-GlcNAc levels in AD patients, such as by inhibiting the action of O-GlcNAcase, one should be able to block hyperphosphorylation of tau and all of the associated effects of tau hyperphosphorylation, including the formation of NFTs and downstream effects. However, because the proper functioning of the β-hexosaminidases is critical, any potential therapeutic intervention for the treatment of AD that blocks the action of O-GlcNAcase would have to avoid the concomitant inhibition of both hexosaminidases A and B.

Neurons do not store glucose and therefore the brain relies on glucose supplied by blood to maintain its essential metabolic functions. Notably, it has been shown that within brain, glucose uptake and metabolism decreases with aging.⁴⁴ Within the brains of AD patients marked decreases in glucose utilization occur and are thought to be a potential cause of neurodegeneration.⁴⁵ The basis for this decreased glucose supply in AD brain⁴⁶⁻⁴⁸ is thought to stem from any of decreased glucose transport,^(49,56) impaired insulin signaling,^(51,52) and decreased blood flow.⁵³

In light of this impaired glucose metabolism, it is worth noting that of all glucose entering into cells, 2-5% is shunted into the hexosamine biosynthetic pathway, thereby regulating cellular concentrations of the end product of this pathway, uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc).⁵⁴ UDP-GlcNAc is a substrate of the nucleocytoplasmic enzyme O-GlcNAc transferase (OGT),²⁻⁵ which acts to post-translationally add GlcNAc to specific serine and threonine residues of numerous nucleocytoplasmic proteins. OGT recognizes many of its substrates^(55,56) and binding partners^(42,57) through its tetratricopeptide repeat (TPR) domains.^(58,59) As described above, O-GlcNAcase^(6,7) removes this post-translational modification to liberate proteins making the O-GlcNAc-modification a dynamic cycle occurring several times during the lifetime of a protein.⁸ O-GlcNAc has been found in several proteins on known phosphorylation sites,^(10,38,39,60) including tau and neurofilaments.⁶¹ Additionally, OGT shows unusual kinetic behaviour making it exquisitely sensitive to intracellular UDP-GlcNAc substrate concentrations and therefore glucose supply.⁴²

Consistent with the known properties of the hexosamine biosynthetic pathway, the enzymatic properties of OGT, and the reciprocal relationship between O-GlcNAc and phosphorylation, it has been shown that decreased glucose availability in brain leads to tau hyperphosphorylation.⁴⁵ Therefore the gradual impairment of glucose transport and metabolism, whatever its causes, leads to decreased O-GlcNAc and hyperphosphorylation of tau (and other proteins). Accordingly, the inhibition of O-GlcNAcase should compensate for the age related impairment of glucose metabolism within the brains of health individuals as well as patients suffering from AD or related neurodegenerative diseases.

These results suggest that a malfunction in the mechanisms regulating tau O-GlcNAc levels may be vitally important in the formation of NFTs and associated neurodegeneration. Good support for blocking tau hyperphosphorylation as a therapeutically useful intervention⁶² comes from recent studies showing that when transgenic mice harbouring human tau are treated with kinase inhibitors, they do not develop typical motor defects³⁴ and, in another case,³³ show decreased levels of insoluble tau. These studies provide a clear link between lowering tau phosphorylation levels and alleviating AD-like behavioural symptoms in a murine model of this disease. Indeed, pharmacological modulation of tau hyperphosphorylation is widely recognized as a valid therapeutic strategy for treating AD and other neurodegenerative disorders.⁶³

Small-molecule O-GlcNAcase inhibitors, to limit tau hyperphosphorylation, have been considered for treatment of AD and related tauopathies.⁶⁴ Specifically, the O-GlcNAcase inhibitor thiamet-G has been implicated in the reduction of tau phosphorylation in cultured PC-12 cells at pathologically relevant sites.⁶⁴ Moreover, oral administration of thiamet-G to healthy Sprague-Dawley rats has been implicated in reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus.⁶⁴

There is also a large body of evidence indicating that increased levels of O-GlcNAc protein modification provides protection against pathogenic effects of stress in cardiac tissue, including stress caused by ischemia, hemorrhage, hypervolemic shock, and calcium paradox. For example, activation of the hexosamine biosynthetic pathway (HBP) by administration of glucosamine has been demonstrated to exert a protective effect in animals models of ischemia/reperfusion,⁶⁵⁻⁷¹ trauma hemorrhage,⁷²⁻⁷⁴ hypervolemic shock,⁷⁵ and calcium paradox.^(65,76) Moreover, strong evidence indicates that these cardioprotective effects are mediated by elevated levels of protein O-GlcNAc modification.^(65,66,68,71,73,76-79) There is also evidence that the O-GlcNAc modification plays a role in a variety of neurodegenerative diseases, including Parkinson's disease and Huntington's disease.⁸⁰

Humans have three genes encoding enzymes that cleave terminal β-N-acetyl-glucosamine residues from glycoconjugates. The first of these encodes O-GlcNAcase. O-GlcNAcase is a member of family 84 of glycoside hydrolases that includes enzymes from organisms as diverse as prokaryotic pathogens to humans (for the family classification of glycoside hydrolases see Coutinho, P. M. & Henrissat, B. (1999) Carbohydrate-Active Enzymes server at URL: http://afmb.cnrs-mrs.fr/CAZY/.^(81,82) O-GlcNAcase acts to hydrolyse O-GlcNAc off of serine and threonine residues of post-translationally modified proteins.^(1,6,7,83,84) Consistent with the presence of O-GlcNAc on many intracellular proteins, the enzyme O-GlcNAcase appears to have a role in the etiology of several diseases including type II diabetes,^(14,85) AD,^(16,21,86) and cancer.^(22,87) Although O-GlcNAcase was likely isolated earlier on,^(18,19) about 20 years elapsed before its biochemical role in acting to cleave O-GlcNAc from serine and threonine residues of proteins was understood.⁶ More recently O-GlcNAcase has been cloned,⁷ partially characterized,²⁰ and suggested to have additional activity as a histone acetyltransferase.²⁰ However, little was known about the catalytic mechanism of this enzyme.

The other two genes, HEXA and HEXB, encode enzymes catalyzing the hydrolytic cleavage of terminal β-N-acetylglucosamine residues from glycoconjugates. The gene products of HEXA and HEXB predominantly yield two dimeric isozymes, hexosaminidase A and hexosaminidase B, respectively. Hexosaminidase A (αβ), a heterodimeric isozyme, is composed of an α- and a β-subunit. Hexosaminidase B (BB), a homodimeric isozyme, is composed of two β-subunits. The two subunits, α- and β-, bear a high level of sequence identity. Both of these enzymes are classified as members of family 20 of glycoside hydrolases and are normally localized within lysosomes. The proper functioning of these lysosomal β-hexosaminidases is critical for human development, a fact that is underscored by the tragic genetic illnesses, Tay-Sach's and Sandhoff diseases which stem from a dysfunction in, respectively, hexosaminidase A and hexosaminidase B.⁸⁸ These enzymatic deficiencies cause an accumulation of glycolipids and glycoconjugates in the lysosomes resulting in neurological impairment and deformation. The deleterious effects of accumulation of gangliosides at the organismal level are still being uncovered.⁸⁹

As a result of the biological importance of these β-N-acetyl-glucosaminidases, small molecule inhibitors of glycosidases^(90,93) have received a great deal of attention,⁹⁴ both as tools for elucidating the role of these enzymes in biological processes and in developing potential therapeutic applications. The control of glycosidase function using small molecules offers several advantages over genetic knockout studies including the ability to rapidly vary doses or to entirely withdraw treatment.

However, a major challenge in developing inhibitors for blocking the function of mammalian glycosidases, including O-GlcNAcase, is the large number of functionally related enzymes present in tissues of higher eukaryotes. Accordingly, the use of non-selective inhibitors in studying the cellular and organismal physiological role of one particular enzyme is complicated because complex phenotypes arise from the concomitant inhibition of such functionally related enzymes. In the case of β-N-acetylglucosaminidases, many compounds that act to block O-GlcNAcase function are non-specific and act potently to inhibit the lysosomal β-hexosaminidases.

A few of the better characterized inhibitors of β-N-acetyl-glucosaminidases which have been used in studies of O-GlcNAc post-translational modification within both cells and tissues are streptozotocin (STZ), 2′-methyl-α-D-glucopyrano-[2,1-d]-Δ2′-thiazoline (NAG-thiazoline) and O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate (PUGNAc).^(14,95-98)

STZ has long been used as a diabetogenic compound because it has a particularly detrimental effect on β-islet cells.⁹⁹ STZ exerts its cytotoxic effects through both the alkylation of cellular DNA^(99,100) as well as the generation of radical species including nitric oxide.¹⁰¹ The resulting DNA strand breakage promotes the activation of poly(ADP-ribose) polymerase (PARP)¹⁰² with the net effect of depleting cellular NAD+ levels and, ultimately, leading to cell death.^(103,104) Other investigators have proposed instead that STZ toxicity is a consequence of the irreversible inhibition of O-GlcNAcase, which is highly expressed within β-islet cells.^(95,105) This hypothesis has, however, been brought into question by two independent research groups.^(106,107) Because cellular O-GlcNAc levels on proteins increase in response to many forms of cellular stress¹⁰⁸ it seems possible that STZ results in increased O-GlcNAc-modification levels on proteins by inducing cellular stress rather than through any specific and direct action on O-GlcNAcase. Indeed, Hanover and coworkers have shown that STZ functions as a poor and somewhat selective inhibitor of O-GlcNAcase¹⁰⁹ and although it has been proposed by others that STZ acts to irreversibly inhibit O-GlcNAcase,¹¹⁰ there has been no clear demonstration of this mode of action. More recently, it has been shown that STZ does not irreversibly inhibit O-GlcNAcase.¹¹¹

NAG-thiazoline has been found to be a potent inhibitor of family 20 hexosaminidases,^(93,112) and more recently, the family 84 O-GlcNAcases.¹¹¹ Despite its potency, a downside to using NAG-thiazoline in a complex biological context is that it lacks selectivity and therefore perturbs multiple cellular processes.

PUGNAc is another compound that suffers from the same problem of lack of selectivity, yet has enjoyed use as an inhibitor of both human O-GlcNAcase^(6,113) and the family 20 human β-hexosaminidases.¹¹⁴ This molecule, developed by Vasella and coworkers, was found to be a potent competitive inhibitor of the β-N-acetyl-glucosaminidases from Canavalia ensiformis, Mucor rouxii, and the β-hexosaminidase from bovine kidney.⁹¹ It has been demonstrated that administration of PUGNAc in a rat model of trauma hemorrhage decreases circulating levels of the pro-inflammatory cytokines TNF-α and IL-6.¹¹⁵ It has also been shown that administration of PUGNAc in a cell-based model of lymphocyte activation decreases production of the cytokine IL-2.¹¹⁶ Subsequent studies have indicated that PUGNAc can be used in an animal model to reduce myocardial infarct size after left coronary artery occlusions.¹¹⁷ Of particular significance is the fact that elevation of O-GlcNAc levels by administration of PUGNAc, an inhibitor of O-GlcNAcase, in a rat model of trauma hemorrhage improves cardiac function.^(115,118) In addition, elevation of O-GlcNAc levels by treatment with PUGNAc in a cellular model of ischemia/reperfusion injury using neonatal rat ventricular myocytes improved cell viability and reduced necrosis and apoptosis compared to untreated cells.¹¹⁹

More recently, it has been suggested that the selective O-GlcNAcase inhibitor NButGT exhibits protective activity in cell-based models of ischemia/reperfusion and cellular stresses, including oxidative stress.¹²⁰ This study suggests the use of O-GlcNAcase inhibitors to elevate protein O-GlcNAc levels and thereby prevent the pathogenic effects of stress in cardiac tissue.

International patent applications PCT/CA2006/000300, filed 1 Mar. 2006, published under No. WO 2006/092049 on 8 Sep. 2006; PCT/CA2007/001554, filed 31 Aug. 2007, published under No. WO 2008/025170 on 6 Mar. 2008; PCT/CA2009/001087, filed 31 Jul. 2009, published under No. WO 2010/012106 on 4 Feb. 2010; PCT/CA2009/001088, filed 31 Jul. 2009, published under WO 2010/012107 on 4 Feb. 2010; PCT/CA2009/001302, filed 16 Sep. 2009, published under WO 2010/037207 on 8 Apr. 2010; PCT/CA2011/000548, filed 10 May 2011, published under No. WO 2011/140640 on 17 Nov. 2011; PCT/CA/2011/001241, filed 8 Nov. 2011, published under WO 2012/061927 on 18 May 2012; and PCT/US2011/059668, filed 8 Nov. 2011, published under WO 2012/064680 on 18 May 2012, describe selective inhibitors of O-GlcNAcase.

SUMMARY OF THE INVENTION

The invention provides, in part, compounds for selectively inhibiting glycosidases, prodrugs of the compounds, uses of the compounds and the prodrugs, pharmaceutical compositions including the compounds or prodrugs of the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.

In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

where X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F.

In alternative embodiments, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

where R¹ and R² may be H and R⁶ may be H, F or OR⁵; or R¹ may be H and R² may be F and R⁶ may be H, F or OR⁵; or R¹ may be F and R² may be H and R⁶ may be H, F or OR⁵; or R¹ may be OR⁵ and R² may be H and R⁶ may be H or F; or R¹ may be H and R² may be OR⁵ and R⁶ may be H, F, or OR⁵; R³ may be H and R⁴ may be OR⁵; or R³ may be OR⁵ and R⁴ may be H; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H.

In alternative embodiments, the invention provides a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof:

where X may be O or S; R¹ and R² may be H and R⁶ may be F; or R¹ may be H and R² may be F and R⁶ may be H, F, or OR⁵; or R¹ may be F and R² may be H and R⁶ may be H, F or OR⁵; or R¹ may be OR⁵ and R² may be H and R⁶ may be F; or R¹ may be H and R² may be OR⁵ and R⁶ may be F; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H.

In alternative embodiments, the invention provides a compound of Formula (Ib) or a pharmaceutically acceptable salt thereof:

where R¹ and R² may be H and R⁶ may be H or OR⁵; or R¹ may be OR⁵ and R² may be H and R⁶ may be H; or R¹ may be H and R² may be OR⁵ and R⁶ may be H; each R⁵ may be independently H or C₁₋₆ acyl; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl.

In alternative embodiments, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

where X may be O or S; R¹ and R² may be independently H, F or OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; each R⁵ may be independently H or acyl; R⁶ may be H, F, or OR⁵; each R⁷ may be independently H or F; each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy; and two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, with the proviso that when R¹ is OR⁵, R² is H; and with the proviso that when R² is OR⁵, R¹ is H; and with the proviso that when R⁶ is OR⁵, each R⁷ is H; and with the proviso that either R¹ or R⁶ is other than OR⁵.

In alternative embodiments, the compound may be a prodrug; the compound may selectively inhibit an O-glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase); the compound may selectively bind an O-GlcNAcase (e.g., a mammalian O-GlcNAcase); the compound may selectively inhibit the cleavage of a 2-acetamido-2-deoxy-β-D-glucopyranoside (O-GlcNAc); the compound may not substantially inhibit a mammalian β-hexosaminidase.

In alternative embodiments, a compound according to Formula (I), Formula (Ia), or Formula (Ib) may have enhanced permeability.

In alternative aspects, the invention provides a pharmaceutical composition including a compound according to the invention, in combination with a pharmaceutically acceptable carrier.

In alternative aspects, the invention provides methods of selectively inhibiting an O-GlcNAcase, or of inhibiting an O-GlcNAcase in a subject in need thereof, or of increasing the level of O-GlcNAc, or of treating a neurodegenerative disease, a tauopathy, cancer or stress, in a subject in need thereof, by administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

where X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F. The condition may be Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Corticobasal degeneration (CBD), Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Multiple system atrophy, Myotonic dystrophy, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Pick's disease (PiD), Post-encephalitic parkinsonism (PEP), Prion diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive supercortical gliosis, Progressive supranuclear palsy (PSP), Richardson's syndrome, Subacute sclerosing panencephalitis, Tangle-only dementia, Huntington's disease, Parkinson's disease, Schizophrenia, Mild Cognitive Impairment (MCI), Neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), or Glaucoma. The stress may be a cardiac disorder, e.g., ischemia; hemorrhage; hypovolemic shock; myocardial infarction; an interventional cardiology procedure; cardiac bypass surgery; fibrinolytic therapy; angioplasty; or stent placement.

In alternative aspects, the invention provides a method of treating an O-GlcNAcase-mediated condition that excludes a neurodegenerative disease, a tauopathy, cancer or stress, in a subject in need thereof, by administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

where X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F. In some embodiments, the condition may be inflammatory or allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias, delayed-type hypersensitivity, atherosclerosis, interstitial lung disease (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, Guillain-Barré syndrome, systemic lupus erythematosus, myastenia gravis, glomerulonephritis, autoimmune thyroiditis, graft rejection, including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinphilic myotis, and eosiniphilic fasciitis; graft rejection, in particular but not limited to solid organ transplants, such as heart, lung, liver, kidney, and pancreas transplants (e.g. kidney and lung allografts); epilepsy; pain; fibromyalgia; stroke, e.g., neuroprotection following a stroke.

In alternative embodiments, X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F. The administering may increase the level of O-GlcNAc in the subject. The subject may be a human.

In alternative aspects, the invention provides use of a compound of an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

where X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F, in the preparation of a medicament. The medicament may be for selectively inhibiting an O-GlcNAcase, for increasing the level of O-GlcNAc, for treating a condition modulated by an O-GlcNAcase, for treating a neurodegenerative disease, a tauopathy, a cancer, or stress.

In alternative aspects, the invention provides a method for screening for a selective inhibitor of an O-GlcNAcase, by a) contacting a first sample with a test compound; b) contacting a second sample with a compound of Formula (I)

where X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F; c) determining the level of inhibition of the O-GlcNAcase in the first and second samples, where the test compound is a selective inhibitor of a O-GlcNAcase if the test compound exhibits the same or greater inhibition of the O-GlcNAcase when compared to the compound of Formula (I).

This summary of the invention does not necessarily describe all features of the invention.

DETAILED DESCRIPTION

The invention provides, in part, novel compounds that are capable of inhibiting an O-glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase). In some embodiments, the O-GlcNAcase is a mammalian O-GlcNAcase, such as a rat, mouse or human O-GlcNAcase.

In some embodiments, one or more of the compounds according to the invention exhibit enhanced permeability. Permeability can be assessed using a variety of standard experimental techniques, including without limitation in situ perfusion, ex vivo tissue diffusion, in vitro cell monolayers (e.g. Caco-2 cells, MDCK cells, LLC-PK1 cells), and artificial cell membranes (e.g. PAMPA assay); suitable techniques for measuring effective permeability (P_(eff)) or apparent peameability (P_(app)) are reviewed for example by Volpe in The AAPS Journal, 2010, 12(4), 670-678. In some embodiments, one or more of the compounds according to the invention show enhanced permeability when tested in one or more of these assays for determining P_(eff) or P_(app). In some embodiments, a compound that exhibits enhanced permeability exhibits greater oral absorption. In some embodiments, a compound that exhibits enhanced permeability exhibits greater brain penetrance when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability achieves higher brain concentrations when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability exhibits a higher brain/plasma concentration ratio when administered in vivo. In some embodiments, “enhanced permeability” means an increase in measured P_(eff) or P_(app) by any value between 10% and 100%, or of any integer value between 10% and 100%, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by 1-fold, 2-fold, or 3-fold, or more, as compared to a suitable reference compound disclosed in for example WO 2006/092049 or WO 2008/025170. In some embodiments, “enhanced permeability” means a measurable P_(app) value (i.e. a value greater than zero) in the assay described below for determination of P_(app) in LLC-PK1 cells. In some embodiments, “enhanced permeability” means a P_(app) value greater than 2×10⁻⁶ cm/s in the assay described below for determination of P_(app) in LLC-PK1 cells. In some embodiments, “enhanced permeability” means a P_(app) value greater than 1×10⁻⁶ cm/s in the assay described below for determination of P_(app) in LLC-PK1 cells. In alternative embodiments, “enhanced permeability” means a P_(app) value in the range 2×10⁻⁶ cm/s to 10×10⁻⁶ cm/s in the assay described below for determination of P_(app) in LLC-PK1 cells.

In some embodiments, a compound according to the invention exhibits superior selectivity in inhibiting an O-GlcNAcase. In some embodiments, one or more of the compounds according to the invention are more selective for an O-GlcNAcase over a β-hexosaminidase. In some embodiments, one or more of the compounds selectively inhibit the activity of a mammalian O-GlcNAcase over a mammalian β-hexosaminidase. In some embodiments, a selective inhibitor of an O-GlcNAcase does not substantially inhibit a β-hexosaminidase. In some embodiments, the β-hexosaminidase is a mammalian β-hexosaminidase, such as a rat, mouse or human β-hexosaminidase. A compound that “selectively” inhibits an O-GlcNAcase is a compound that inhibits the activity or biological function of an O-GlcNAcase, but does not substantially inhibit the activity or biological function of a β-hexosaminidase. For example, in some embodiments, a selective inhibitor of an O-GlcNAcase selectively inhibits the cleavage of 2-acetamido-2-deoxy-β-D-glucopyranoside (O-GlcNAc) from polypeptides. In some embodiments, a selective inhibitor of an O-GlcNAcase selectively binds to an O-GlcNAcase. In some embodiments, a selective inhibitor of an O-GlcNAcase inhibits hyperphosphorylation of a tau protein and/or inhibits formations of NFTs. By “inhibits,” “inhibition” or “inhibiting” means a decrease by any value between 10% and 90%, or of any integer value between 30% and 60%, or over 100%, or a decrease by 1-fold, 2-fold, 5-fold, 10-fold or more. It is to be understood that the inhibiting does not require full inhibition. In some embodiments, a selective inhibitor of an O-GlcNAcase elevates or enhances O-GlcNAc levels e.g., O-GlcNAc-modified polypeptide or protein levels, in cells, tissues, or organs (e.g., in brain, muscle, or heart (cardiac) tissue) and in animals. By “elevating” or “enhancing” is meant an increase by any value between 10% and 90%, or of any integer value between 30% and 60%, or over 100%, or an increase by 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold or more. In some embodiments, a selective inhibitor of an O-GlcNAcase exhibits a selectivity ratio, as described herein, in the range 10 to 100000, or in the range 100 to 100000, or in the range 1000 to 100000, or at least 10, 20, 50, 100, 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 10,000, 25,000, 50,000, 75,000, or any value within or about the described range.

One or more of the compounds of the present invention elevate O-GlcNAc levels on O-GlcNAc-modified polypeptides or proteins in vivo specifically via interaction with an O-GlcNAcase enzyme, and are effective in treating conditions which require or respond to inhibition of O-GlcNAcase activity.

In some embodiments, one or more of the compounds of the present invention are useful as agents that produce a decrease in tau phosphorylation and NFT formation. In some embodiments, one or more of the compounds are therefore useful to treat Alzheimer's disease and related tauopathies. In some embodiments, one or more of the compounds are thus capable of treating Alzheimer's disease and related tauopathies by lowering tau phosphorylation and reducing NFT formation as a result of increasing tau O-GlcNAc levels. In some embodiments, one or more of the compounds produce an increase in levels of O-GlcNAc modification on O-GlcNAc-modified polypeptides or proteins, and are therefore useful for treatment of disorders responsive to such increases in O-GlcNAc modification; these disorders include without limitation neurodegenerative, inflammatory, cardiovascular, and immunoregulatory diseases. In some embodiments, a compound is also useful as a result of other biological activities related to their ability to inhibit the activity of glycosidase enzymes. In alternative embodiments, one or more of the compounds of the invention are valuable tools in studying the physiological role of O-GlcNAc at the cellular and organismal level.

In alternative embodiments, the invention provides methods of enhancing or elevating levels of protein O-GlcNAc modification in animal subjects, such as, veterinary and human subjects. In alternative embodiments, the invention provides methods of selectively inhibiting an O-GlcNAcase enzyme in animal subjects, such as, veterinary and human subjects. In alternative embodiments, the invention provides methods of inhibiting phosphorylation of tau polypeptides, or inhibiting formation of NFTs, in animal subjects, such as, veterinary and human subjects.

In specific embodiments, the invention provides compounds described generally by Formula (I) and the salts, prodrugs, and enantiomeric forms thereof:

As set forth in Formula (I): X may be O or S; R¹ and R² may be H, or R¹ may be H and R² may be F, or R¹ may be F and R² may be H, or R¹ may be OR⁵ and R² may be H, or R¹ may be H and R² may be OR⁵; R³ may be OR⁵ and R⁴ may be H, or R³ may be H and R⁴ may be OR⁵; R⁶ may be H, F, or OR⁵; each R⁵ may be independently H or C₁₋₆ acyl; each R⁷ may be independently H or F; and each R⁸ may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; where when R⁶ is OR⁵, then each R⁷ may be H; and where when R¹ is OR⁵, then R⁶ may be H or F; and where when R⁶ is OR⁵, then R¹ may be H or F.

In some embodiments, X as set forth in Formula (I) may be O or S.

In some embodiments, R¹ as set forth in Formula (I) may be H, F, OH, or OC(O)R⁹, where R⁹ may be H, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl. In some embodiments, R¹ may be H, F or OH. In some embodiments, R¹ may be H or OH.

In some embodiments, R² as set forth in Formula (I) may be H, F, OH, or OC(O)R⁹, where R⁹ may be H, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl. In some embodiments, R² may be H, F or OH. In some embodiments, R² may be H or F.

In some embodiments, R³ as set forth in Formula (I) may be H, OH, or OC(O)R⁹, where R⁹ may be H, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl. In some embodiments, R³ may be H or OH. In some embodiments, R³ may be H.

In some embodiments, R⁴ as set forth in Formula (I) may be H, OH, or OC(O)R⁹, where R⁹ may be H, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl. In some embodiments, R⁴ may be H or OH. In some embodiments, R⁴ may be OH.

In some embodiments, R⁵ as set forth in Formula (I) may be H or C(O)R⁹, where R⁹ may be H, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl. In some embodiments, R⁵ may be H.

In some embodiments, R⁶ as set forth in Formula (I) may be H, F, OH, or OC(O)R⁹, where R⁹ may be H, C₁₋₆ alkyl, or C₃₋₆ cycloalkyl. In some embodiments, R⁶ may be H, F, or OH.

In some embodiments, each R⁷ as set forth in Formula (I) may be independently H or F.

In some embodiments, each R⁸ as set forth in Formula (I) may be independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy, where the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy may be optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl. In some embodiments, each R⁸ may be independently H, CH₃, or CH₂CH₃.

In some embodiments, the two R⁸ groups as set forth in Formula (I) may be connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl.

In some embodiments, NR⁸ ₂ as set forth in Formula (I), may be optionally substituted

where X may be CR¹⁰ ₂, NR¹⁰, O, C═O, O(C═O), (C═O)O, NR¹⁰(C═O), or (C═O)NR¹⁰; where each R¹⁰ may be independently H or C₁₋₄ alkyl; and n may be an integer between 0 and 3. In some embodiments, NR⁸ ₂ may be optionally substituted 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, morpholin-4-yl, 1-piperizinyl, azetidin-2-one-1-yl, pyrrolidin-2-one-1-yl, or piperid-2-one-1-yl. In some embodiments, NR⁸ ₂ may be

In specific embodiments of the invention, compounds according to Formula (I) include the compounds described in Table 1.

TABLE 1 Example Name Structure  1 (3aR,4R,5R,6S,7aS)-2-(ethylamino)-6- (fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 2 (3aR,4R,5R,6S,7aS)-6-(fluoromethyl)-2- (methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 3 rac-(3aR,4R,5R,6S,7aS)-2-(ethylamino)- 6-(fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 4 (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6- (fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 5 (3aR,4R,5R,6S,7aS)-2-(dimethylamino)- 6-(fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 6 (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 7 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(dimethylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 8 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

 9 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(ethylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

10 (3aS,4S,5R,6R,7aS)-2-(azetidin-1-yl)-4- fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

11 (3aS,4S,5R,6R,7aS)-2-(dimethylamino)- 4-fluoro-6-(hydroxymethyl)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

12 (3aS,4S,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

13 (3aS,4S,5R,6R,7aS)-2-(ethylamino)-4- fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

14 (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)- 4-fluoro-2-(methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

15 (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-4-fluoro-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

16 (3aR,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

17 (3aR,4R,5S,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

18 (3aR,4S,5S,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

19 (3aS,4R,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

20 (3aS,4R,5S,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

21 (3aS,4S,5S,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

22 (3aR,5S,6R,7aS)-2-(azetidin-1-yl)-6- (hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

23 (3aR,5R,6R,7aS)-2-(azetidin-1-yl)-6- (hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

24 (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6- methyl-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

25 (3aR,4S,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]thiazol- 5-ol

26 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]thiazole-4,5-diol

27 (3aS,4S,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(pyrrolidin-1-yl)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

28 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(pyrrolidin-1-yl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

29 (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-4- fluoro-6-(fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

30 (3aS,4S,5R,6S,7aS)-4-fluoro-6- (fluoromethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

31 (3aS,4S,5R,6S,7aS)-4-fluoro-6- (fluoromethyl)-2-(pyrrolidin-1-yl)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

32 (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)- 4-fluoro-2-(pyrrolidin-1-yl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

As will be appreciated by a person skilled in the art, Formula (I) above may also be represented alternatively as follows:

As used herein the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. For example, “a compound” refers to one or more of such compounds, while “the enzyme” includes a particular enzyme as well as other family members and equivalents thereof as known to those skilled in the art.

Throughout this application, it is contemplated that the term “compound” or “compounds” refers to the compounds discussed herein and includes precursors and derivatives of the compounds, including acyl-protected derivatives, and pharmaceutically acceptable salts of the compounds, precursors, and derivatives. The invention also includes prodrugs of the compounds, pharmaceutical compositions including the compounds and a pharmaceutically acceptable carrier, and pharmaceutical compositions including prodrugs of the compounds and a pharmaceutically acceptable carrier.

The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry is specified, the invention is meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion.

“Alkyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation and including, for example, from one to ten carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is attached to the rest of the molecule by a single bond. In alternative embodiments, the alkyl group may contain from one to six carbon atoms, such as 1, 2, 3, 4, 5, or 6 carbon atoms. Unless stated otherwise specifically in the specification, the alkyl group may be optionally substituted by one or more substituents as described herein. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkyl group.

“Alkenyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one double bond and including, for example, from two to ten carbon atoms, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is attached to the rest of the molecule by a single bond or a double bond. In alternative embodiments, the alkenyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless stated otherwise specifically in the specification, the alkenyl group may be optionally substituted by one or more substituents as described herein. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkenyl group.

“Alkynyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one triple bond and including, for example, from two to ten carbon atoms. In alternative embodiments, the alkynyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless stated otherwise specifically in the specification, the alkynyl group may be optionally substituted by one or more substituents as described herein.

“Acyl” refers to a group of the formula —C(O)R_(a), where R_(a) is a C₁₋₁₀ alkyl, or a C₁₋₆ alkyl, or a C₃₋₁₅ cycloalkyl group as described herein. The alkyl or cycloalkyl group(s) may be optionally substituted as described herein.

“Alkoxy” refers to a group of the formula —OR_(b), where R_(b) is a C₁₋₁₀ alkyl or a C₁₋₆ alkyl group as described herein. The alkyl group(s) may be optionally substituted as described herein.

“Cycloalkyl” refers to a stable monovalent monocyclic, bicyclic or tricyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having for example from 3 to 15 carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond. In alternative embodiments, the cycloalkyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless otherwise stated specifically herein, the term “cycloalkyl” is meant to include cycloalkyl groups which are optionally substituted as described herein.

In some embodiments, two R⁸ groups as set forth in Formula (I) may be connected together with the nitrogen atom to which they are attached to form a ring. In these embodiments, “ring” refers to a stable nitrogen-containing monocyclic group having 3 to 6 members that may be saturated or monounsaturated. In alternative embodiments, the ring may include C, H and N atoms. In other embodiments, the ring may include heteroatoms, for example O and S. Examples of a ring in these embodiments include 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, 1-piperidinyl, 1,2,3,6-tetrahydropyridin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-piperizinyl, azetidin-2-one-1-yl, pyrrolidin-2-one-1-yl, piperid-2-one-1-yl, 1,2-oxazetidin-2-yl, isoxazolidin-2-yl, and 1,2-oxazinan-2-yl. The ring in these embodiments may be optionally substituted as described herein.

“Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs one or more times and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl group may or may not be substituted and that the description includes both substituted alkyl groups and alkyl groups having no substitution, and that said alkyl groups may be substituted one or more times. Examples of optionally substituted alkyl groups include, without limitation, methyl, ethyl, propyl, etc. and including cycloalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.; examples of optionally substituted alkenyl groups include allyl, crotyl, 2-pentenyl, 3-hexenyl, 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc. In some embodiments, optionally substituted alkyl and alkenyl groups include C₁₋₆ alkyls or alkenyls.

Therapeutic Indications

The invention provides methods of treating conditions that are modulated, directly or indirectly, by an O-GlcNAcase enzyme or by O-GlcNAc-modified protein levels, for example, a condition that is benefited by inhibition of an O-GlcNAcase enzyme or by an elevation of O-GlcNAc-modified protein levels. Such conditions include, without limitation, Glaucoma, Schizophrenia, tauopathies, such as Alzheimer's disease, neurodegenerative diseases, cardiovascular diseases, diseases associated with inflammation, diseases associated with immunosuppression and cancers. One or more of the compounds of the invention are also useful in the treatment of diseases or disorders related to deficiency or over-expression of O-GlcNAcase or accumulation or depletion of O-GlcNAc, or any disease or disorder responsive to glycosidase inhibition therapy. Such diseases and disorders include, but are not limited to, Glaucoma, Schizophrenia, neurodegenerative disorders, such as Alzheimer's disease (AD), or cancer. Such diseases and disorders may also include diseases or disorders related to the accumulation or deficiency in the enzyme OGT. Also included is a method of protecting or treating target cells expressing proteins that are modified by O-GlcNAc residues, the dysregulation of which modification results in disease or pathology. The term “treating” as used herein includes treatment, prevention, and amelioration.

In alternative embodiments, the invention provides methods of enhancing or elevating levels of protein O-GlcNAc modification in animal subjects, such as, veterinary and human subjects. This elevation of O-GlcNAc levels can be useful for the prevention or treatment of Alzheimer's disease; prevention or treatment of other neurodegenerative diseases (e.g. Parkinson's disease, Huntington's disease); providing neuroprotective effects; preventing damage to cardiac tissue; and treating diseases associated with inflammation or immunosuppression.

In alternative embodiments, the invention provides methods of selectively inhibiting an O-GlcNAcase enzyme in animal subjects, such as veterinary and human subjects.

In alternative embodiments, the invention provides methods of inhibiting phosphorylation of tau polypeptides, or inhibiting formation of NFTs, in animal subjects, such as, veterinary and human subjects. Accordingly, a compound of the invention may be used to study and treat AD and other tauopathies.

In general, the methods of the invention are effected by administering a compound according to the invention to a subject in need thereof, or by contacting a cell or a sample with a compound according to the invention, for example, a pharmaceutical composition comprising a therapeutically effective amount of the compound according to Formula (I). More particularly, they are useful in the treatment of a disorder in which the regulation of O-GlcNAc protein modification is implicated, or any condition as described herein. Disease states of interest include Alzheimer's disease (AD) and related neurodegenerative tauopathies, in which abnormal hyperphosphorylation of the microtubule-associated protein tau is involved in disease pathogenesis. In some embodiments, a compound may be used to block hyperphosphorylation of tau by maintaining elevated levels of O-GlcNAc on tau, thereby providing therapeutic benefit.

The effectiveness of a compound in treating pathology associated with the accumulation of toxic tau species (for example, Alzheimer's disease and other tauopathies) may be confirmed by testing the ability of a compound to block the formation of toxic tau species in established cellular¹²¹⁻¹²³ and/or transgenic animal models of disease.^(33,34)

Tauopathies that may be treated with a compound of the invention include: Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Corticobasal degeneration (CBD), Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Multiple system atrophy, Myotonic dystrophy, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Pick's disease (PiD), Post-encephalitic parkinsonism (PEP), Prion diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive supercortical gliosis, Progressive supranuclear palsy (PSP), Richardson's syndrome, Subacute sclerosing panencephalitis, Tangle-only dementia, and Glaucoma.

One or more of the compounds of this invention are also useful in the treatment of conditions associate with tissue damage or stress, stimulating cells, or promoting differentiation of cells. Accordingly, in some embodiments, a compound of this invention may be used to provide therapeutic benefit in a variety of conditions or medical procedures involving stress in cardiac tissue, including but not limited to: ischemia; hemorrhage; hypovolemic shock; myocardial infarction; an interventional cardiology procedure; cardiac bypass surgery; fibrinolytic therapy; angioplasty; and stent placement.

The effectiveness of a compound in treating pathology associated with cellular stress (including ischemia, hemorrhage, hypovolemic shock, myocardial infarction, and other cardiovascular disorders) may be confirmed by testing the ability of a compound to prevent cellular damage in established cellular stress assays,^(108,119,120) and to prevent tissue damage and promote functional recovery in animal models of ischemia-reperfusion,^(71,117) and trauma-hemorrhage.^(73,115,118)

Compounds that selectively inhibit O-GlcNAcase activity may be used for the treatment of diseases that are associated with inflammation, including but not limited to, inflammatory or allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias, delayed-type hypersensitivity, atherosclerosis, interstitial lung disease (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, Guillain-Barré syndrome, systemic lupus erythematosus, myastenia gravis, glomerulonephritis, autoimmune thyroiditis, graft rejection, including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinphilic myotis, eosiniphilic fasciitis; and cancers.

In addition, compounds that affects levels of protein O-GlcNAc modification may be used for the treatment of diseases associated with immunosuppression, such as in individuals undergoing chemotherapy, radiation therapy, enhanced wound healing and burn treatment, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy) or combination of conventional drugs used in the treatment of autoimmune diseases and graft/transplantation rejection, which causes immunosuppression; or immunosuppression due to congenital deficiency in receptor function or other causes.

One or more of the compounds of the invention may be useful for treatment of neurodegenerative diseases, including Parkinson's disease and Huntington's disease. Other conditions that may be treated are those triggered, affected, or in any other way correlated with levels of O-GlcNAc post-translational protein modification. It is expected that one or more of the compounds of this invention may be useful for the treatment of such conditions and in particular, but not limited to, the following for which a association with O-GlcNAc levels on proteins has been established: graft rejection, in particular but not limited to solid organ transplants, such as heart, lung, liver, kidney, and pancreas transplants (e.g. kidney and lung allografts); cancer, in particular but not limited to cancer of the breast, lung, prostate, pancreas, colon, rectum, bladder, kidney, ovary; as well as non-Hodgkin's lymphoma and melanoma; epilepsy, pain, fibromyalgia, or stroke, e.g., for neuroprotection following a stroke.

Pharmaceutical & Veterinary Compositions, Dosages, and Administration

Pharmaceutical compositions including compounds according to the invention, or for use according to the invention, are contemplated as being within the scope of the invention. In some embodiments, pharmaceutical compositions including an effective amount of a compound of Formula (I) are provided.

The compounds of Formula (I) and their pharmaceutically acceptable salts, enantiomers, solvates, and derivatives are useful because they have pharmacological activity in animals, including humans. In some embodiments, one or more of the compounds according to the invention are stable in plasma, when administered to a subject.

In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with any other active agents or pharmaceutical compositions where such combined therapy is useful to modulate O-GlcNAcase activity, for example, to treat neurodegenerative, inflammatory, cardiovascular, or immunoregulatory diseases, or any condition described herein. In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with one or more agents useful in the prevention or treatment of Alzheimer's disease. Examples of such agents include, without limitation,

-   -   acetylcholine esterase inhibitors (AChEIs) such as Aricept®         (Donepezil), Exelon®(Rivastigmine), Razadyne® (Razadyne ER®,         Reminyl®, Nivalin®, Galantamine), Cognex® (Tacrine), Dimebon,         Huperzine A, Phenserine, Debio-9902 SR (ZT-1 SR), Zanapezil         (TAK0147), ganstigmine, NP7557, etc.;     -   NMDA receptor antagonists such as Namenda® (Axura®, Akatinol®,         Ebixa®, Memantine), Dimebon, SGS-742, Neramexane, Debio-9902 SR         (ZT-1 SR), etc.;     -   gamma-secretase inhibitors and/or modulators such as Flurizan™         (Tarenflurbil, MPC-7869, R-flurbiprofen), LY450139, MK 0752,         E2101, BMS-289948, BMS-299897, BMS-433796, LY-411575, GSI-136,         etc.;     -   beta-secretase inhibitors such as ATG-Z1, CTS-21166, MK-8931,         etc.;     -   alpha-secretase activators, such as NGX267, etc;     -   amyloid-β aggregation and/or fibrillization inhibitors such as         Alzhemed™ (3APS, Tramiprosate, 3-amino-1-propanesulfonic acid),         AL-108, AL-208, AZD-103, PBT2, Cereact, ONO-2506PO, PPI-558,         etc.;     -   tau aggregation inhibitors such as methylene blue, etc.;     -   microtubule stabilizers such as AL-108, AL-208, paclitaxel,         etc.;     -   RAGE inhibitors, such as TTP488, etc.;     -   5-HT 1a receptor antagonists, such as Xaliproden, Lecozotan,         etc.;     -   5-HT4 receptor antagonists, such as PRX-03410, etc.;     -   kinase inhibitors such as SRN-003-556, amfurindamide, LiCl,         AZD1080, NP031112, SAR-502250, etc.     -   humanized monoclonal anti-Aβ antibodies such as Bapineuzumab         (AAB-001), LY2062430, RN1219, ACU-5A5, etc.;     -   amyloid vaccines such as AN-1792, ACC-001, etc.;     -   neuroprotective agents such as Cerebrolysin, AL-108, AL-208,         Huperzine A, etc.;     -   L-type calcium channel antagonists such as MEM-1003, etc.;     -   nicotinic receptor antagonists, such as AZD3480, GTS-21, etc.;     -   nicotinic receptor agonists, such as MEM 3454, Nefiracetam,         etc.;     -   peroxisome proliferator-activated receptor (PPAR) gamma agonists         such as Avandia® (Rosglitazone), etc.;     -   phosphodiesterase IV (PDE4) inhibitors, such as MK-0952, etc.;     -   hormone replacement therapy such as estrogen (Premarin), etc.;     -   monoamine oxidase (MAO) inhibitors such as NS2330, Rasagiline         (Azilect®), TVP-1012, etc.;     -   AMPA receptor modulators such as Ampalex (CX 516), etc.;     -   nerve growth factors or NGF potentiators, such as CERE-110         (AAV-NGF), T-588, T-817MA, etc.;     -   agents that prevent the release of luteinizing hormone (LH) by         the pituitary gland, such as leuoprolide (VP-4896), etc.;     -   GABA receptor modulators such as AC-3933, NGD 97-1, CP-457920,         etc.;     -   benzodiazepine receptor inverse agonists such as SB-737552         (S-8510), AC-3933, etc.;     -   noradrenaline-releasing agents such as T-588, T-817MA, etc.

It is to be understood that combination of compounds according to the invention, or for use according to the invention, with Alzheimer's agents is not limited to the examples described herein, but includes combination with any agent useful for the treatment of Alzheimer's disease. Combination of compounds according to the invention, or for use according to the invention, and other Alzheimer's agents may be administered separately or in conjunction. The administration of one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).

In alternative embodiments, a compound may be supplied as a “prodrug” or protected forms, which release the compound after administration to a subject. For example, a compound may carry a protective group which is split off by hydrolysis in body fluids, e.g., in the bloodstream, thus releasing the active compound or is oxidized or reduced in body fluids to release the compound. Accordingly, a “prodrug” is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term “prodrug” refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention. Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a subject.

The term “prodrug” is also meant to include any covalently bonded carriers which release the active compound of the invention in vivo when such prodrug is administered to a subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention. Prodrugs include compounds of the invention where a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and acetamide, formamide, and benzamide derivatives of amine functional groups in one or more of the compounds of the invention and the like.

A discussion of prodrugs may be found in “Smith and Williams' Introduction to the Principles of Drug Design,” H. J. Smith, Wright, Second Edition, London (1988); Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996); A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113 191 (Harwood Academic Publishers, 1991); Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14; or in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, all of which are incorporated in full by reference herein.

Suitable prodrug forms of one or more of the compounds of the invention include embodiments in which one or more R⁵ as set forth in Formula (I) is C(O)R, where R is optionally substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl. In these cases the ester groups may be hydrolyzed in vivo (e.g. in bodily fluids), releasing the active compounds in which each R⁵ is H. Preferred prodrug embodiments of the invention include compounds of Formula (I) where one or more R⁵ is C(O)CH₃.

Compounds according to the invention, or for use according to the invention, can be provided alone or in combination with other compounds in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, diluent or excipient, in a form suitable for administration to a subject such as a mammal, for example, humans, cattle, sheep, etc. If desired, treatment with a compound according to the invention may be combined with more traditional and existing therapies for the therapeutic indications described herein. Compounds according to the invention may be provided chronically or intermittently. “Chronic” administration refers to administration of the compound(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. “Intermittent” administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature. The terms “administration,” “administrable,” or “administering” as used herein should be understood to mean providing a compound of the invention to the subject in need of treatment.

“Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that has been approved, for example, by the United States Food and Drug Administration or other governmental agency as being acceptable for use in humans or domestic animals.

A compound of the present invention may be administered in the form of a pharmaceutically acceptable salt. In such cases, pharmaceutical compositions in accordance with this invention may comprise a salt of such a compound, preferably a physiologically acceptable salt, which are known in the art. In some embodiments, the term “pharmaceutically acceptable salt” as used herein means an active ingredient comprising compounds of Formula I used in the form of a salt thereof, particularly where the salt form confers on the active ingredient improved pharmacokinetic properties as compared to the free form of the active ingredient or other previously disclosed salt form.

A “pharmaceutically acceptable salt” includes both acid and base addition salts. A “pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

A “pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

Thus, the term “pharmaceutically acceptable salt” encompasses all acceptable salts including but not limited to acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartarate, mesylate, borate, methylbromide, bromide, methylnitrite, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutame, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydradamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like.

Pharmaceutically acceptable salts of a compound of the present invention can be used as a dosage for modifying solubility or hydrolysis characteristics, or can be used in sustained release or prodrug formulations. Also, pharmaceutically acceptable salts of a compound of this invention may include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.

Pharmaceutical formulations will typically include one or more carriers acceptable for the mode of administration of the preparation, be it by injection, inhalation, topical administration, lavage, or other modes suitable for the selected treatment. Suitable carriers are those known in the art for use in such modes of administration.

Suitable pharmaceutical compositions may be formulated by means known in the art and their mode of administration and dose determined by the skilled practitioner. For parenteral administration, a compound may be dissolved in sterile water or saline or a pharmaceutically acceptable vehicle used for administration of non-water soluble compounds such as those used for vitamin K. For enteral administration, the compound may be administered in a tablet, capsule or dissolved in liquid form. The table or capsule may be enteric coated, or in a formulation for sustained release. Many suitable formulations are known, including, polymeric or protein microparticles encapsulating a compound to be released, ointments, gels, hydrogels, or solutions which can be used topically or locally to administer a compound. A sustained release patch or implant may be employed to provide release over a prolonged period of time. Many techniques known to skilled practitioners are described in Remington: the Science & Practice of Pharmacy by Alfonso Gennaro, 20^(th) ed., Williams & Wilkins, (2000). Formulations for parenteral administration may, for example, contain excipients, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of a compound. Other potentially useful parenteral delivery systems for modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

A compound or a pharmaceutical composition according to the present invention may be administered by oral or non-oral, e.g., intramuscular, intraperitoneal, intravenous, intracisternal injection or infusion, subcutaneous injection, transdermal or transmucosal routes. In some embodiments, a compound or pharmaceutical composition in accordance with this invention or for use in this invention may be administered by means of a medical device or appliance such as an implant, graft, prosthesis, stent, etc. Implants may be devised which are intended to contain and release such compounds or compositions. An example would be an implant made of a polymeric material adapted to release the compound over a period of time. A compound may be administered alone or as a mixture with a pharmaceutically acceptable carrier e.g., as solid formulations such as tablets, capsules, granules, powders, etc.; liquid formulations such as syrups, injections, etc.; injections, drops, suppositories, pessaryies. In some embodiments, compounds or pharmaceutical compositions in accordance with this invention or for use in this invention may be administered by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.

A compound of the invention may be used to treat animals, including mice, rats, horses, cattle, sheep, dogs, cats, and monkeys. However, a compound of the invention can also be used in other organisms, such as avian species (e.g., chickens). One or more of the compounds of the invention may also be effective for use in humans. The term “subject” or alternatively referred to herein as “patient” is intended to be referred to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. However, one or more of the compounds, methods and pharmaceutical compositions of the present invention may be used in the treatment of animals. Accordingly, as used herein, a “subject” may be a human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc. The subject may be suspected of having or at risk for having a condition requiring modulation of O-GlcNAcase activity.

An “effective amount” of a compound according to the invention includes a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as inhibition of an O-GlcNAcase, elevation of O-GlcNAc levels, inhibition of tau phosphorylation, or any condition described herein. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as inhibition of an O-GlcNAcase, elevation of O-GlcNAc levels, inhibition of tau phosphorylation, or any condition described herein. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount. A suitable range for therapeutically or prophylactically effective amounts of a compound may be any integer from 0.1 nM-0.1 M, 0.1 nM-0.05 M, 0.05 nM-15 μM or 0.01 nM-10 μM.

In alternative embodiments, in the treatment or prevention of conditions which require modulation of O-GlcNAcase activity, an appropriate dosage level will generally be about 0.01 to 500 mg per kg subject body weight per day, and can be administered in singe or multiple doses. In some embodiments, the dosage level will be about 0.1 to about 250 mg/kg per day. It will be understood that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound used, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the patient undergoing therapy.

It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners. The amount of active compound(s) in the composition may vary according to factors such as the disease state, age, sex, and weight of the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. In general, compounds of the invention should be used without causing substantial toxicity, and as described herein, one or more of the compounds exhibit a suitable safety profile for therapeutic use. Toxicity of a compound of the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances however, such as in severe disease conditions, it may be necessary to administer substantial excesses of the compositions.

In the compounds of generic Formula (I), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula (I). For example, different isotopic forms of hydrogen (H) include protium (¹H), deuterium (²H) and tritium (³H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.

Other Uses and Assays

A compound of Formula (I) may be used in screening assays for compounds which modulate the activity of glycosidase enzymes, preferably the O-GlcNAcase enzyme. The ability of a test compound to inhibit O-GlcNAcase-dependent cleavage of O-GlcNAc from a model substrate may be measured using any assays, as described herein or known to one of ordinary skill in the art. For example, a fluorescence or UV-based assay known in the art may be used. A “test compound” is any naturally-occurring or artificially-derived chemical compound. Test compounds may include, without limitation, peptides, polypeptides, synthesised organic molecules, naturally occurring organic molecules, and nucleic acid molecules. A test compound can “compete” with a known compound such as a compound of Formula (I) by, for example, interfering with inhibition of O-GlcNAcase-dependent cleavage of O-GlcNAc or by interfering with any biological response induced by a compound of Formula (I).

Generally, a test compound can exhibit any value between 10% and 200%, or over 500%, modulation when compared to a compound of Formula (I) or other reference compound. For example, a test compound may exhibit at least any positive or negative integer from 10% to 200% modulation, or at least any positive or negative integer from 30% to 150% modulation, or at least any positive or negative integer from 60% to 100% modulation, or any positive or negative integer over 100% modulation. A compound that is a negative modulator will in general decrease modulation relative to a known compound, while a compound that is a positive modulator will in general increase modulation relative to a known compound.

In general, test compounds are identified from large libraries of both natural products or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the method(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographic Institute (Ft. Pierce, Fla., USA), and PharmaMar, MA, USA. In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

When a crude extract is found to modulate inhibition of O-GlcNAcase-dependent cleavage of O-GlcNAc, or any biological response induced by a compound of Formula (I), further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having O-GlcNAcase-inhibitory activities. The same assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for treatment are chemically modified according to methods known in the art. Compounds identified as being of therapeutic, prophylactic, diagnostic, or other value may be subsequently analyzed using a suitable animal model, as described herein on known in the art.

In some embodiments, one or more of the compounds are useful in the development of animal models for studying diseases or disorders related to deficiencies in O-GlcNAcase, over-expression of O-GlcNAcase, accumulation of O-GlcNAc, depletion of O-GlcNAc, and for studying treatment of diseases and disorders related to deficiency or over-expression of O-GlcNAcase, or accumulation or depletion of O-GlcNAc. Such diseases and disorders include neurodegenerative diseases, including Alzheimer's disease, and cancer.

Various alternative embodiments and examples of the invention are described herein. These embodiments and examples are illustrative and should not be construed as limiting the scope of the invention.

EXAMPLES

The following examples are intended to illustrate embodiments of the invention and are not intended to be construed in a limiting manner.

Abbreviations

-   BCl₃=boron trichloride -   DCM=dichloromethane -   DIPEA=diisopropylethylamine -   DMF=N,N-dimethylformamide -   DMP=Dess-Martin periodinane -   DMSO=dimethyl sulfoxide -   EtOAc=ethyl acetate -   NBS=N-bromosuccinimide -   TBDMSCl=tert-butyldimethylsilyl chloride -   THF=tetrahydrofuran

Example 1 (3aR,4R,5R,6S,7aS)-2-(Ethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol

To a solution of rac-((((1R,2R,6R)-6-((benzyloxy)methyl)cyclohex-3-ene-1,2-diyl)bis-(oxy))bis(methylene))dibenzene (Carb. Res., 1990, 204, 51-64; Carb. Res., 1990, 206, 352-60) (3.71 g, 9.02 mmol) in DMSO (40 mL) and water (0.487 mL, 27.1 mmol) at 10° C. was added freshly recrystallised NBS (3.21 g, 18.04 mmol) in one portion. The mixture (which slowly became a yellow solution) was stirred at room temperature for 2.5 h. The reaction was diluted with aqueous satd. NaHCO₃ (300 mL) and extracted with EtOAc (2×150 mL). The combined extracts were washed with brine and dried over MgSO₄. Solvents were evaporated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 20-30% EtOAc in hexanes to give a mixture of rac-(1S,2R,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-bromocyclohexanol and a diastereomeric side-product in a 9:1 ratio, respectively (4.35 g, 95%). An NMR sample was obtained by a second silica gel column eluted with 20% EtOAc in hexanes. The major product exhibited ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.20 (m, 15H), 4.68 (d, J=11.2 Hz, 1H), 4.63 (d, J=11.5 Hz, 1H), 4.57 (d, J=11.5 Hz, 1H), 4.47 (d, J=11.5 Hz, 1H), 4.41 (d, J=12.1 Hz, 1H), 4.39 (d, J=12.1 Hz, 1H), 4.33 (dd, J=6.0, 3.5 Hz, 1H), 4.12 (m, 1H), 3.87 (dd, J=6.8, 3.5 Hz, 1H), 3.77 (t, J=6.8 Hz, 1H), 3.58-3.53 (m, 2H), 2.31-2.23 (m, 1H), 2.20 (ddd, J=13.6, 8.8, 3.6 Hz, 1H), 1.82 (dt, J=14.0, 5.4 Hz, 1H).

To a solution of the mixture obtained above (3.82 g, 7.47 mmol) in dry DCM (26 mL) at 0° C. was added a solution of benzoylisocyanate (90%, 1.19 g, 8.01 mmol) in dry DCM (6 mL) dropwise. The mixture was stirred at room temperature for 1.5 h. Solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 40-50% Et₂O in hexanes to give the product rac-(1S,2R,3S, 4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-bromocyclohexyl benzoyl-carbamate (4.20 g, 85%) as white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (s, 1H), 7.79 (d, J=7.2 Hz, 2H), 7.60 (t, J=7.2 Hz, 1H), 7.49 (t, J=7.6 Hz, 2H), 7.38-7.23 (m, 15H), 5.34 (q, J=4.0 Hz, 1H), 4.86 (d, J=11.2 Hz, 1H), 4.72 (d, J=11.6 Hz, 1H), 4.62 (d, J=11.6 Hz, 1H), 4.55 (m, 1H), 4.52 (d, J=10.8 Hz, 1H), 4.46 (s, 2H), 3.84 (t, J=8.4 Hz, 1H), 3.79 (dd, J=8.4, 3.6 Hz, 1H), 3.60 (dd, J=9.2, 6.0 Hz, 1H), 3.52 (dd, J=9.2, 3.6 Hz, 1H), 2.43 (ddd, J=14.8, 11.6, 2.8 Hz, 1H), 2.18-2.09 (m, 1H), 2.00 (dtd, J=14.8, 4.0, 1.2 Hz, 1H).

To a solution of above product (390 mg, 0.593 mmol) in dry THF (10 mL) at 0° C. was added NaH (60%, 45 mg, 1.13 mmol) After stirring at room temperature for 1.5 h, the mixture was heated at reflux for 20 h. Solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with 20-50% EtOAc in hexanes to give rac-(3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-hexahydrobenzo[d]oxazol-2(3H)-one as a white solid (110 mg, 46%). ¹H NMR (400 MHz, CDCl₃): δ 7.53 (d, J=8.0 Hz, 2H), 7.45 (t, J=7.6 Hz, 1H), 7.39-7.17 (m, 15H), 7.08 (d, J=8.0 Hz, 2H), 4.99-4.93 (m, 2H), 4.67 (d, J=12.0 Hz, 1H), 4.63 (d, J=12.0 Hz, 1H), 4.53 (d, J=12.0 Hz, 1H), 4.49 (d, J=12.0 Hz, 1H), 4.32 (d, J=11.2 Hz, 1H), 4.27 (d, J=11.2 Hz, 1H), 4.24 (t, J=2.4 Hz, 1H), 3.71 (dt, J=5.6, 1.6 Hz, 1H), 3.52-3.47 (m, 2H), 2.32-2.24 (m, 1H), 2.12-2.03 (m, 2H).

The above racemic material was resolved by preparative chiral HPLC using a Chiralpak IA column (4.6*15 cm, Sum), eluting with hexane:EtOH 70:30 to give optically pure (>99.9% ee) (3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)hexahydrobenzo[d]oxazol-2(3H)-one (first eluting, [α]_(D)=+110.33°, DCM as solvent). This material exhibited a ¹H NMR spectrum identical to that of the racemic material described above.

To a solution of (3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)hexahydrobenzo[d]oxazol-2(3H)-one (3.00 g, 6.34 mmol) in acetic anhydride (60 mL) and acetic acid (10 mL) was added anhydrous ZnCl₂ (8.62 g, 63.4 mmol). The mixture was stirred at room temperature for 3 h. Most of the solvents were removed by evaporation under high vacuum. The residue was diluted with aqueous saturated NaHCO₃ (200 mL) and extracted with EtOAc (2×50 mL). The extracts were washed with brine, dried with MgSO₄. The solvent was evaporated to give white foam. This was dissolved in MeOH (50 mL) and K₂CO₃ (1.75 g, 12.7 mmol) was added. The mixture was stirred at room temperature for 2 h. Solvent was evaporated. The residue was diluted with water (50 mL) and extracted with DCM (2×30 mL). The extracts were washed with brine, dried with MgSO₄. The solvent was evaporated to give white foam which was purified by a silica gel column, eluting with 5% MeOH in DCM to give 3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one as a white solid (1.86 g, 77%). ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.42 (m, 10H), 4.95 (d, J=11.8 Hz, 1H), 4.89 (d, J=10.9 Hz, 1H), 4.82 (s, 1H), 4.69 (d, J=11.3 Hz, 1H), 4.64-4.69 (m, 1H), 4.60 (d, J=11.8 Hz, 1H), 3.72-3.77 (m, 1H), 3.50-3.56 (m, 3H), 3.40 (t, J=9.1 Hz, 1H), 2.12 (dt, J=15.3 Hz, 3.1 Hz, 1H), 1.91-1.98 (m, 1H), 1.69-1.77 (m, 1H), 1.55 (t, J=4.9 Hz, 1H).

To a solution of (3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (1.86 g, 4.86 mmol) in pyridine (11 mL) at −20° C. was added MeSO₂Cl (0.723 g, 6.31 mmol). The mixture was slowly warmed to room temperature and stirred for 4 h. The reaction was diluted with aqueous saturated NH₄Cl (100 mL) and extracted with EtOAc (2×60 mL). The extracts were washed with 0.5 N HCl (3×60 mL), dried with MgSO4. The solvent was evaporated to give ((3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-2-oxooctahydrobenzo[d]oxazol-6-yl)methyl methanesulfonate as a white solid (2.25 g, 100%) which was pure enough for next reaction. MS m/z 484.1 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.44 (m, 10H), 4.92 (d, J=11.9 Hz, 1H), 4.87 (d, J=11.1 Hz, 1H), 4.66-4.70 (m, 2H), 4.65 (d, J=11.0 Hz, 1H), 4.57 (d, J=11.9 Hz, 1H), 4.43 (dd, J=9.7 Hz, 4.2 Hz, 1H), 4.21 (dd, J=9.7 Hz, 3.0 Hz, 1H), 3.59 (t, J=6.8 Hz, 1H), 3.51 (t, J=7.6 Hz, 1H), 3.41 (t, J=8.9 Hz, 1H), 2.12-2.26 (m, 2H), 1.79-1.87 (m, 1H).

To a solution of ((3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-2-oxooctahydrobenzo[d]oxazol-6-yl)methyl methanesulfonate (2.24 g, 4.86 mmol) in dry acetonitrile (12 mL) at room temperature was added a solution of tetrabutylammonium fluoride (4.933 g, 24.3 mmol) in dry acetonitrile (16 mL). The mixture was heated at reflux under N₂ for 4 h. Solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (150 mL), washed with water (2×) and brine, and dried with MgSO₄. The solvent was evaporated to give the crude product. This was purified by SiO₂ column, eluted with 30-50% EtOAc in hexanes to give (3aS,4R,5R,6S,7aS)-4,5-bis(benzyloxy)-6-(fluoromethyl)hexahydrobenzo[d]oxazol-2(3H)-one (810 mg, 43%). MS m/z 408.1 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.31-7.42 (m, 10H), 4.99 (s, 1H), 4.93 (d, J=11.7 Hz, 1H), 4.84 (d, J=11.0 Hz, 1H), 4.79 (dd, J=9.2 Hz, 3.2 Hz, 0.5H), 4.65-4.71 (m, 1.5H), 4.65 (d, J=11.1 Hz, 1H), 4.59 (d, J=11.7 Hz, 1H), 4.37 (ddd, J=47.4 Hz, 9.2 Hz, 2.3 Hz, 1H), 3.58 (t, J=6.8 Hz, 1H), 3.51 (t, J=7.8 Hz, 1H), 3.44 (t, J=8.9 Hz, 1H), 2.22 (dt, J=14.9 Hz, 2.9 Hz, 1H), 1.94-2.10 (m, 1H), 1.85-1.93 (m, 1H).

A mixture of (3aS,4R,5R,6S,7aS)-4,5-bis(benzyloxy)-6-(fluoromethyl)hexahydrobenzo[d]oxazol-2(3H)-one (410 mg, 1.065 mmol) in ethanol (8 mL), water (8 mL) and 5 N NaOH (4 mL) was heated at reflux for 2 h. After cooling, the reaction was diluted with water (50 mL), extracted with DCM (3×25 mL) and dried with Na₂SO₄. The solvent was evaporated to give (1S,2S,3R,4R,5S)-2-amino-3,4-bis(benzyloxy)-5-(fluoromethyl)cyclohexanol as a white solid (370 mg, 97%) which was pure enough for next reaction. MS m/z 382.2 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.29-7.39 (m, 10H), 5.03 (d, J=11.4 Hz, 1H), 4.91 (d, J=10.9 Hz, 1H), 4.78 (ddd, J=48.0 Hz, 9.0 Hz, 3.0 Hz, 1H), 4.67 (d, J=10.9 Hz, 1H), 4.65 (d, J=11.4 Hz, 1H), 4.37 (ddd, J=47.4 Hz, 9.1 Hz, 2.0 Hz, 1H), 3.88 (br s, 1H), 3.58 (t, J=9.4 Hz, 1H), 3.48 (t, J=9.9 Hz, 1H), 2.11-2.26 (m, 1H), 1.95 (dt, J=14.3 Hz, 3.1 Hz, 1H), 1.63 (t, J=13.6 Hz, 1H).

To a solution of (1S,2S,3R,4R,5S)-2-amino-3,4-bis(benzyloxy)-5-(fluoromethyl)cyclohexanol (182 mg, 0.507 mmol) in THF (4 mL) at room temperature was added a solution of ethylthioisocyanate (55 mg, 0.63 mmol) in THF (1 mL). The mixture was stirred at room temperature for 18 h. The solvent was evaporated to give a colorless syrup. This was dissolved in acetone (3 mL) and MeI (144 mg, 1.01 mmol) was added. The mixture was stirred at room temperature for 6 h. The reaction was diluted with saturated aqueous NaHCO₃ (20 mL) and extracted with DCM (3×10 mL). The extracts were dried with Na₂SO₄ and the solvents were evaporated to give (3aS,4R,5R,6S,7aS)-4,5-bis(benzyloxy)-N-ethyl-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-2-amine as a white solid (209 mg, 100%) which was pure enough for next reaction. MS m/z 413.2 (M+1, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.39 (m, 10H), 4.86 (d, J=11.7 Hz, 1H), 4.80 (d, J=11.2 Hz, 1H), 4.70 (d, J=11.6 Hz, 1H), 4.69-4.73 (m, 1H), 4.64 (dd, J=9.0 Hz, 4.5 Hz, 0.5H), 4.45-4.53 (m, 1H), 4.48 (d, J=11.2 Hz, 1H), 4.35 (dd, J=8.9 Hz, 2.9 Hz, 0.5H), 4.09 (dd, J=8.0 Hz, 5.2 Hz, 1H), 3.67 (t, J=5.6 Hz, 1H), 3.46 (dd, J=9.3 Hz, 6.1 Hz, 1H), 3.16-3.29 (m, 2H), 2.12 (dt, J=14.6 Hz, 2.9 Hz, 1H), 1.91-2.06 (m, 1H), 1.79-1.87 (m, 1H), 1.15 (t, J=7.2 Hz, 3H).

To a solution of (3aS,4R,5R,6S,7aS)-4,5-bis(benzyloxy)-N-ethyl-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-2-amine (209 mg, 0.507 mmol) in DCM (5 mL) at −78° C. was added a solution of BCl₃ in DCM (1.0 M, 1.27 mL, 1.27 mmol). The mixture was slowly warmed up to 0° C. and stirred at this temperature for 5 h. The reaction was cooled to −78° C. again and a 1:1 mixture of MeOH-DCM (10 mL) was added dropwise to quench the reaction. Solvents were evaporated and the residue was treated with MeOH for three more times. The crude product was purified by silica gel column chromatography, eluted with 5%-15% 2 M NH₃ MeOH solution in DCM to give the product (3aR,4R,5R,6S,7aS)-2-(ethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol (86.0 mg, 73%) as a white solid. MS m/z 233.2 (M+1, 100%); ¹H NMR (400 MHz, MeOD) δ 4.60 (dd, J=9.0 Hz, 4.4 Hz, 0.5H), 4.45-4.51 (m, 2H), 4.35 (dd, J=9.0 Hz, 2.5 Hz, 0.5H), 3.47 (t, J=7.1 Hz, 1H), 3.13-3.22 (m, 2H), 3.06-3.12 (m, 2H), 2.12-2.21 (m, 1H), 1.65-1.80 (m, 2H), 1.06 (t, J=7.3 Hz, 3H); ¹³C NMR (100 MHz, MeOD) δ 163.88, 84.63 (d, J=165.6 Hz), 80.81, 80.65, 71.86 (d, J=4.8 Hz), 68.43, 39.40 (d, J=18.6 Hz), 38.23 (d, J=2.4 Hz), 28.14 (d, J=3.8 Hz), 15.24.

The following examples were synthesized according to procedures analogous to the schemes and examples outlined above.

TABLE 2 Example Structure Name 2

(3aR,4R,5R,6S,7aS)-6-(fluoromethyl)-2- (methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol ¹H NMR (500 MHz, MeOD) δ 4.68 (br s, 1H), 4.47 (ddd, J = 47.4 Hz, 9.0 Hz, 4.6 Hz, 1H), 4.32 (ddd, J = 47.4 Hz, 9.0 Hz, 2.8 Hz, 1H), 3.57 (t, J = 7.1 Hz, 1H), 3.09-3.15 (m, 2H), 2.68 (s, 3H), 2.14 (d, J = 14.9 Hz, 1H), 1.59-1.77 (m, 2H); ¹³C NMR (125 MHz, MeOD) δ 164.38, 84.86 (d, J = 165.6 Hz), 83.01, 80.65, 79.58, 71.35 (d, J = 4.6 Hz), 65.53, 39.33 (d, J = 18.7 Hz), 29.16 (d, J = 1.4 Hz), 27.71 (d, J = 3.8 Hz); MS, (ES, m/z) [M + H]⁺ 219.2. 3

rac-(3aR,4R,5R,6S,7aS)-2-(ethylamino)- 6-(fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol ¹H NMR (400 MHz, MeOD) δ 4.60 (dd, J = 9.0 Hz, 4.4 Hz, 0.5H), 4.45-4.51 (m, 2H), 4.35 (dd, J = 9.0 Hz, 2.5 Hz, 0.5H), 3.47 (t, J = 7.1 Hz, 1H), 3.13-3.22 (m, 2H), 3.06-3.12 (m, 2H), 2.12-2.21 (m, 1H), 1.65-1.80 (m, 2H), 1.06 (t, J = 7.3 Hz, 3H); ¹³C NMR (100 MHz, MeOD) δ 163.88, 84.63 (d, J = 165.6 Hz), 80.81, 80.65, 71.86 (d, J = 4.8 Hz), 68.43, 39.40 (d, J = 18.6 Hz), 38.23 (d, J = 2.4 Hz), 28.14 (d, J = 3.8 Hz), 15.24; MS, (ES, m/z) [M + H]⁺ 233.2.

Example 4 (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol

To a solution of (3aS,4R,5R,6S,7aS)-4,5-bis(benzyloxy)-6-(fluoromethyl)hexahydrobenzo[d]oxazol-2(3H)-one (193 mg, 0.503 mmol) in DCM (4 mL) at room temperature was added 4 A molecular sieves (130 mg) followed by trimethyloxonium tetrafluoroborate (372 mg, 2.52 mmol). The mixture was stirred at room temperature under N₂ for 24 h. Azetidine hydrochloride (236 mg, 2.52 mmol) and a solution of Et₃N (279 mg) in THF (2.0 mL) was added. The mixture was stirred at room temperature for another 48 h. The reaction was diluted with saturated aqueous NaHCO₃ (20 mL) and extracted with DCM (2×15 mL). The extracts were dried with Na₂SO₄ and the solvents were evaporated to give the crude product. This was purified by silica gel column, eluted with 2%-5% 2 M NH₃ MeOH solution in DCM to yield (3aS,4R,5R,6S,7aS)-2-(azetidin-1-yl)-4,5-bis(benzyloxy)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole as a white solid (80.0 mg, 38%). MS m/z 425.2 (M+1, 100%); ¹H NMR (500 MHz, CDCl₃) δ 7.28-7.36 (m, 10H), 4.93-4.96 (m, 1H), 4.77 (d, J=11.7 Hz, 1H), 4.71 (d, J=11.1 Hz, 1H), 4.65 (d, J=11.7 Hz, 1H), 4.54 (dd, J=9.0 Hz, 5.0 Hz, 1H), 4.49 (d, J=11.2 Hz, 1H), 4.43-4.46 (m, 1H), 4.43 (d, J=11.1 Hz, 1H), 4.34 (dd, J=9.0 Hz, 4.7 Hz, 1H), 4.20 (dd, J=8.3 Hz, 3.7 Hz, 1H), 3.88-3.99 (m, 4H), 3.86 (t, J=4.3 Hz, 1H), 3.53 (t, J=5.7 Hz, 1H), 2.09-2.19 (m, 4H), 1.81-1.87 (m, 1H).

To a solution of (3aS,4R,5R,6S,7aS)-2-(azetidin-1-yl)-4,5-bis(benzyloxy)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole (80.0 mg, 0.189 mmol) in DCM (2 mL) at −78° C. was added a solution of BCl₃ in DCM (1.0 M, 0.47 mL, 0.47 mmol). The mixture was slowly warmed up to 0° C. and stirred at this temperature for 5 h. The reaction was cooled to −78° C. again and a 1:1 mixture of MeOH-DCM (5 mL) was added dropwise to quench the reaction. Solvents were evaporated and the residue was treated with MeOH for three more times. The crude product was purified by silica gel column chromatography, eluted with 3%-8% 2 M NH₃ MeOH solution in DCM to give the product (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol (36.5 mg, 79%) as a white solid. MS m/z 267.2 (M+23, 100%); ¹H NMR (400 MHz, MeOD) δ 4.61-4.69 (m, 1.5H), 4.53-4.57 (m, 1H), 4.43 (dd, J=9.0 Hz, 2.8 Hz, 1H), 4.00 (t, J=7.6 Hz, 1H), 3.58 (t, J=7.2 Hz, 1H), 3.15-3.28 (m, 2H), 2.22-2.36 (m, 3H), 1.75-1.87 (m, 2H); ¹³C NMR (100 MHz, MeOD) δ 164.81, 85.13 (d, J=160.7 Hz), 81.98, 80.60 (d, J=0.6 Hz), 71.88 (d, J=4.8 Hz), 69.03, 39.37 (d, J=18.6 Hz), 28.09 (d, J=3.9 Hz), 17.75.

The following example was synthesized according to procedures analogous to the schemes and examples outlined above.

TABLE 3 Example Structure Name 5

(3aR,4R,5R,6S,7aS)-2-(dimethylamino)-6- (fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol ¹H NMR (500 MHz, MeOD) δ 4.77-4.80 (m, 1H), 4.59 (ddd, J = 47.4 Hz, 9.0 Hz, 4.5 Hz, 1H), 4.46 (ddd, J = 47.4 Hz, 9.0 Hz, 2.8 Hz, 1H), 3.65-3.68 (m, 1H), 3.20-3.26 (m, 2H), 2.95 (s, 6H), 2.29 (dt, J = 14.6 Hz, 2.9 Hz, 1H), 1.72-1.88 (m, 2H); ¹³C NMR (100 MHz, MeOD) δ 164.06, 84.94 (d, J = 165.8 Hz), 83.40, 79.89, 71.49 (d, J = 4.8 Hz), 66.70, 39.33 (d, J = 18.6 Hz), 37.95, 27.83 (d, J = 4.1 Hz); MS, (ES, m/z) [M + H]⁺ 233.2.

Example 6 (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol

To a solution of (3aR,4R,5R,6R,7aS)-4,5-dihydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (2.23 g, 11.0 mmol) in DMF (15 mL) at room temperature was added imidazole (2.24 g, 33.0 mmol) followed by TBDMSCl (1.98 g, 13.2 mmol). The mixture was stirred at this temperature for 2.5 h. The mixture was diluted with water (150 mL) and extracted with EtOAc (5×50 mL). The extracts were dried with MgSO₄ and the solvents were evaporated. The crude product was purified by silica gel column chromatography, eluted with 5% MeOH in DCM to give the product (3aR,4R,5R,6R,7aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-4,5-dihydroxyhexahydrobenzo[d]oxazol-2(3H)-one (2.57 g, 74%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.68-4.71 (m, 1H), 3.85 (dd, J=8.0 Hz, 3.2 Hz, 1H), 3.63 (dd, J=8.0 Hz, 5.2 Hz, 1H), 3.47-3.55 (m, 2H), 3.37 (t, J=7.8 Hz, 1H), 2.14 (dt, J=12.5 Hz, 2.3 Hz, 1H), 1.86-1.94 (m, 1H), 1.52-1.58 (m, 1H), 0.89 (s, 9H), 0.08 (s, 6H).

To a solution of (3aR,4R,5R,6R,7aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-4,5-dihydroxyhexahydrobenzo[d]oxazol-2(3H)-one (2.21 g, 7.00 mmol) and 4-dimethylaminopyridine (30 mg, 0.24 mmol) in pyridine (20 mL) at 0° C. was added benzoyl chloride (3.92 g, 27.9 mmol) dropwise. The mixture was stirred at room temperature for 20 h. The reaction was diluted with EtOAc (300 mL), washed with saturated aqueous NaHCO₃ water (2×150 mL), 0.5 N HCl (2×100 mL) and brine and dried over MgSO₄. The solvent was evaporated to give the crude product. This was purified by basic alumina column, eluted with 10-30% EtOAc in hexanes to provide (3aS,4R,5R,6R,7aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (3.29 g, 90%). ¹H NMR (400 MHz, CDCl₃) δ 7.92-7.97 (m, 4H), 7.49-7.53 (m, 2H), 7.35-7.39 (m, 4H), 6.07 (s, 1H), 5.53 (t, J=10.1 Hz, 1H), 5.13 (dd, J=9.6 Hz, 6.6 Hz, 1H), 4.91-4.94 (m, 1H), 3.89 (t, J=7.0 Hz, 1H), 3.79 (dd, J=10.0 Hz, 4.0 Hz, 1H), 3.61 (dd, J=10.0 Hz, 2.6 Hz, 1H), 2.40 (dt, J=15.5 Hz, 3.0 Hz, 1H), 2.27-2.36 (m, 1H), 2.03-2.11 (m, 1H), 0.87 (s, 9H), −0.03 (s, 3H), −0.07 (s, 3H).

To a suspension of (3 aS,4R,5R,6R,7aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (3.29 g, 6.27 mmol) in dry MeOH (50 mL) at room temperature was added a solution of HCl in 4:1 EtOAc-MeOH (1.5 M, 28 mL, 41.8 mmol). The mixture was stirred at room temperature for 2 h. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 60-80% EtOAc in hexanes to give (3aS,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (1.87 g, 73%). MS m/z 434.1 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J=7.8 Hz, 2H), 7.87 (d, J=7.8 Hz, 2H), 7.49 (t, J=7.8 Hz, 2H), 7.33 (t, J=7.8 Hz, 4H), 6.37 (s, 1H), 5.45 (dd, J=9.7 Hz, 6.8 Hz, 1H), 5.31 (t, J=10.0 Hz, 1H), 4.90-4.92 (m, 1H), 3.88 (t, J=6.8 Hz, 1H), 3.74 (dd, J=12.1 Hz, 2.5 Hz, 1H), 3.57 (dd, J=12.1 Hz, 2.0 Hz, 1H), 2.39 (d, J=13.8 Hz, 1H), 2.19-2.32 (m, 2H).

To a solution of (3 aS,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (1.76 g, 4.28 mmol) in dry DCM (40 mL) at 0° C. was added DMP (2.72 g, 6.42 mmol). The mixture was then stirred at room temperature for 4 h. The reaction was diluted with saturated aqueous NaHCO3 (20 mL) and 1 M Na₂S₂O₃ (30 mL) and extracted with EtOAc (2×50 mL). The extracts were dried over MgSO₄ and the solvents were evaporated to give (3aS,4R,5R,6S,7aS)-6-formyl-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (1.75 g, 100%) which was carried onto next reaction without further purification. ¹H NMR (400 MHz, CDCl₃) δ 9.82 (s, 1H), 7.95 (d, J=7.8 Hz, 2H), 7.88 (d, J=7.8 Hz, 2H), 7.47-7.54 (m, 2H), 7.32-7.38 (m, 4H), 6.48 (s, 1H), 5.66 (t, J=8.2 Hz, 1H), 5.50 (dd, J=7.7 Hz, 5.8 Hz, 1H), 4.94-4.97 (m, 1H), 4.00 (t, J=6.6 Hz, 1H), 3.26-3.32 (m, 1H), 2.56 (dt, J=12.1 Hz, 2.5 Hz, 1H), 2.10-2.18 (m, 1H).

To a solution of (3aS,4R,5R,6S,7aS)-6-formyl-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (580 mg, 1.42 mmol) in dry DCM (10 mL) at 0° C. under N₂ was added a solution of acetyl chloride (223 mg, 2.84 mmol) in dry DCM (2.84 mL) followed by a solution of DIPEA (330 mg, 2.56 mmol) in dry DCM (2.56 mL) dropwise. The mixture was stirred at 0° C. for 2 h. The reaction was further diluted with DCM (20 mL), washed with 0.1 N HCl and brine. The solvent was evaporated to give the crude (3aS,4R,5R,6S,7aS)-3-acetyl-6-formyl-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (614 mg, 96%) which was carried onto next reaction without further purification. ¹H NMR (400 MHz, CDCl₃) δ 9.89 (s, 1H), 7.93 (d, J=7.8 Hz, 2H), 7.90 (d, J=7.8 Hz, 2H), 7.54-7.59 (m, 2H), 7.40-7.44 (m, 4H), 5.79 (dd, J=5.7 Hz, 4.1 Hz, 1H), 5.68 (t, J=5.7 Hz, 1H), 5.01-5.04 (m, 1H), 4.82 (dd, J=7.7 Hz, 4.0 Hz, 1H), 3.13-3.19 (m, 1H), 2.54-2.60 (m, 1H), 2.50 (s, 3H), 2.26-2.34 (m, 1H).

To a solution of (3aS,4R,5R,6S,7aS)-3-acetyl-6-formyl-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (614 mg, 1.36 mmol) in dry DCM (10 mL) at 0° C. was added bis(2-methoxyethyl)aminosulfur trifluoride (1.24 g, 5.60 mmol). The mixture was stirred at room temperature under N₂ for 20 h. The mixture was slowly diluted with saturated aqueous NaHCO₃ (20 mL), extracted with DCM (3×). The extracts were washed with brine and dried with MgSO₄. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 20-35% EtOAc in hexanes to give (3aS,4R,5R,6S,7aS)-3-acetyl-6-(difluoromethyl)-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (408 mg, 63%). MS m/z 496.1 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.94 (t, J=8.0 Hz, 4H), 7.54-7.59 (m, 2H), 7.54-7.58 (m, 2H), 7.42 (t, J=7.7 Hz, 4H), 6.15 (td, J=55.9 Hz, 2.0 Hz, 1H), 5.68 (t, J=5.1 Hz, 1H), 5.48 (t, J=6.1 Hz, 1H), 5.03-5.06 (m, 1H), 4.85 (dd, J=7.6 Hz, 4.4 Hz, 1H), 2.62-2.76 (m, 1H), 2.53-2.60 (m, 1H), 2.49 (s, 3H), 2.21-2.29 (m, 1H).

To a suspension of (3aS,4R,5R,6S,7aS)-3-acetyl-6-(difluoromethyl)-2-oxooctahydrobenzo[d]oxazole-4,5-diyl dibenzoate (892 mg, 1.89 mmol) in MeOH (20 mL) was added K₂CO₃ (781 mg, 5.66 mmol). The mixture was stirred at room temperature for 2 h. The solvent was evaporated and the residue was purified by SiO₂ column, eluted with 5%-10% MeOH in DCM to give (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-4,5-dihydroxyhexahydrobenzo[d]oxazol-2(3H)-one (256 mg, 69%) and N-((1S,2R,3R,4S,6S)-4-(difluoromethyl)-2,3,6-trihydroxycyclohexyl)acetamide (176 mg, 31%), both were as a white solid. (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-4,5-dihydroxyhexahydrobenzo[d]oxazol-2(3H)-one: MS m/z 246.1 (M+23, 100%); ¹H NMR (400 MHz, MeOD) δ 6.18 (td, J=56.6 Hz, 1.3 Hz, 1H), 4.74-4.78 (m, 1H), 3.51 (t, J=6.9 Hz, 1H), 3.30-3.38 (m, 2H), 2.25 (dt, J=15.4 Hz, 3.2 Hz, 1H), 2.01-2.16 (m, 1H), 1.82-1.90 (m, 1H). N-((1S,2R,3R,4S,6S)-4-(difluoromethyl)-2,3,6-trihydroxycyclohexyl)acetamide: MS m/z 240.1 (M+1, 100%); ¹H NMR (400 MHz, MeOD) δ 5.98 (t, J=55.1 Hz, 1H), 3.89 (br s, 1H), 3.46-3.57 (m, 2H), 3.14-3.23 (m, 1H), 2.05-2.20 (m, 1H), 2.00 (s, 3H), 1.76 (dt, J=14.2 Hz, 3.6 Hz, 1H), 1.34-1.42 (m, 1H)

To a solution of (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-4,5-dihydroxyhexahydrobenzo[d]oxazol-2(3H)-one (255 mg, 1.48 mmol) in MeOH (2 mL) and water (3 mL) was added LiOH (600 mg, 25.0 mmol). The mixture was heated at reflux for 2 h. Solvents were evaporated and the residue was purified by silica gel column chromatography, eluted with 20% 2 M NH₃ MeOH solution in DCM to give the product (1R,2R,3S,4S,6S)-3-amino-6-(difluoromethyl)cyclohexane-1,2,4-triol (214 mg, 99%) as a white solid. MS m/z 198.1 (M+1, 100%); ¹H NMR (400 MHz, MeOD) δ 6.14 (t, J=57.2 Hz, 1H), 4.15 (br s, 1H), 3.63 (t, J=9.7 Hz, 1H), 3.30 (t, J=11.0 Hz, 1H), 2.91 (dd, J=10.4 Hz, 2.8 Hz, 1H), 2.20-2.36 (m, 1H), 1.97 (dt, J=14.4 Hz, 3.6 Hz, 1H), 1.53-1.60 (m, 1H).

To a solution of N-((1S,2R,3R,4S,6S)-4-(difluoromethyl)-2,3,6-trihydroxycyclohexyl)acetamide (176 mg, 1.48 mmol) in EtOH (2 mL) and water (3 mL) was added NaOH (736 mg, 18.4 mmol). The mixture was heated at reflux for 2 h. Solvents were evaporated and the residue was purified by silica gel column chromatography, eluted with 20% 2 M NH₃ MeOH solution in DCM to give the product (1R,2R,3S,4S,6S)-3-amino-6-(difluoromethyl)cyclohexane-1,2,4-triol (90.0 mg, 62%) as a white solid.

To a solution of (1R,2R,3S,4S,6S)-3-amino-6-(difluoromethyl)cyclohexane-1,2,4-triol (300 mg, 1.52 mmol) in DMF (3 mL) at room temperature was added thiocarbonyldiimidazole (298 mg, 1.67 mmol). The mixture was stirred at room temperature for 4 h. Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 5%-8% MeOH in DCM to give the product (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-4,5-dihydroxyhexahydrobenzo[d]oxazole-2(3H)-thione (238 mg, 65%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 6.20 (t, J=57.4 Hz, 1H), 4.92-4.96 (m, 1H), 3.71 (t, J=7.1 Hz, 1H), 3.26-3.38 (m, 2H), 2.35 (dt, J=15.3 Hz, 3.0 Hz, 1H), 2.03-2.17 (m, 1H), 1.91-1.99 (m, 1H).

To a solution of (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-4,5-dihydroxyhexahydrobenzo[d]oxazole-2(3H)-thione (233 mg, 0.97 mmol) in EtOH (5 mL) was added MeI (277 mg, 1.95 mmol) and 5 N NaOH (0.21 mL, 1.1 mmol). The mixture was stirred at room temperature for 2 h. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 3%-5% MeOH in DCM to give (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(methylthio)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol (218 mg, 88%) as a pale yellow solid. MS m/z 254.1 (M+1, 100%); ¹H NMR (400 MHz, MeOD) δ 6.16 (td, J=56.8 Hz, 1.8 Hz, 1H), 4.79-4.83 (m, 1H), 3.85 (t, J=7.6 Hz, 1H), 3.39 (t, J=9.0 Hz, 1H), 3.28 (t, J=7.9 Hz, 1H), 2.48 (s, 3H), 2.27 (dt, J=14.7 Hz, 3.6 Hz, 1H), 1.91-2.10 (m, 2H).

To a solution of (3 aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(methylthio)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol (52.6 mg, 0.208 mmol) in EtOH (5 mL) was added azetidine hydrochloride (97 mg, 1.04 mmol). The mixture was heated at reflux for 5 h. After cooling, solid NaHCO₃ (200 mg, 2.38 mmol) was added and stirred for 10 min Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 5% 2 M NH₃ MeOH solution in DCM to give the product (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol (46.2 mg, 85%) as a white solid. MS m/z 263.1 (M+1, 100%); ¹H NMR (400 MHz, MeOD) δ 6.14 (td, J=56.8 Hz, 1.8 Hz, 1H), 4.66-4.69 (m, 1H), 4.00 (t, J=7.6 Hz, 4H), 3.62 (t, J=7.2 Hz, 1H), 3.34 (t, J=9.2 Hz, 1H), 3.24 (t, J=7.9 Hz, 1H), 2.29-2.36 (m, 2H), 2.21 (dt, J=15.1 Hz, 3.6 Hz, 1H), 1.95-2.10 (m, 1H), 1.82-1.90 (m, 1H); ¹³C NMR (100 MHz, MeOD) δ 164.62, 117.96 (t, J=238.5 Hz), 81.20, 79.89 (d, J=1.6 Hz), 71.36 (dd, J=7.2 Hz, 1.0 Hz), 68.72, 51.91, 42.25 (t, J=19.8 Hz), 22.61 (t, J=4.7 Hz), 17.75.

The following examples were synthesized according to procedures analogous to the schemes and examples outlined above.

TABLE 4 Example Structure Name 7

(3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2- (dimethylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol ¹H NMR (400 MHz, MeOD) δ 6.15 (td, J = 56.8 Hz, 1.7 Hz, 1H), 4.65-4.69 (m, 1H), 3.59 (t, J = 7.3 Hz, 1H), 3.37 (t, J = 9.3 Hz, 1H), 3.22 (t, J = 8.0 Hz, 1H), 2.91 (s, 6H), 2.26 (dt, J = 15.1 Hz, 3.4 Hz, 1H), 1.96-2.10 (m, 1H), 1.82-1.90 (m, 1H); ¹³C NMR (100 MHz, MeOD) δ 164.71, 117.94 (t, J = 238.4 Hz), 81.20, 80.29 (d, J = 1.7 Hz), 71.44 (dd, J = 7.3 Hz, 1.0 Hz), 68.86, 42.29 (t, J = 19.8 Hz), 37.71, 22.64 (dd, J = 5.1 Hz, 4.3 Hz); MS, (ES, m/z) [M + H]⁺ 251.2. 8

(3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2- (methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol ¹H NMR (400 MHz, MeOD) δ 6.10 (td, J = 56.6 Hz, 2.0 Hz, 1H), 5.09-5.12 (m, 1H), 3.90 (t, J = 7.0 Hz, 1H), 3.36-3.44 (m, 2H), 2.88 (s, 3H), 2.30 (d, J = 14.8 Hz, 1H), 1.94-2.14 (m, 2H); ¹³C NMR (100 MHz, MeOD) δ 163.87, 117.70 (t, J = 238.8 Hz), 84.03, 77.42, 70.35 (dd, J = 6.9 Hz, 1.4 Hz), 62.21, 42.12 (t, J = 19.7 Hz), 29.15, 22.12 (t, J = 5.2 Hz); MS, (ES, m/z) [M + H]⁺ 237.2. 9

(3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2- (ethylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol ¹H NMR (400 MHz, MeOD) δ 6.07 (td, J = 56.7 Hz, 2.0 Hz, 1H), 5.06-5.10 (m, 1H), 3.89 (t, J = 7.0 Hz, 1H), 3.35-3.41 (m, 2H), 3.25 (q, J = 7.2 Hz, 2H), 2.27 (d, J = 14.6 Hz, 1H), 1.92- 2.10 (m, 2H), 1.16 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, MeOD) δ 163.01, 117.73 (t, J = 238.8 Hz), 83.74, 77.27, 70.30 (dd, J = 6.8 Hz, 1.3 Hz), 62.11, 42.14 (t, J = 19.8 Hz), 38.89, 22.09 (t, J = 5.1 Hz), 14.41; MS, (ES, m/z) [M + H]⁺ 251.2.

Example 10 (3aS,4S,5R,6R,7aS)-2-(azetidin-1-yl)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol

To a solution of (3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)hexahydrobenzo[d]oxazol-2(3H)-one (7.35 g, 15.5 mmol) in DCM (80 mL) at −78° C. was added a solution of BCl₃ in DCM (1.0 M, 53 mL, 53 mmol). The mixture was slowly warmed up to 0° C. and stirred at this temperature for 4 h. The reaction was cooled to −78° C. again and a 1:1 mixture of MeOH-DCM (50 mL) was added dropwise to quench the reaction. Solvents were evaporated and the residue was treated with MeOH for three more times. The crude product was purified by silica gel column chromatography, eluted with 5%-15% MeOH in DCM to give the product of (3aR,4R,5R,6R,7aS)-4,5-dihydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (2.99 g, 95%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.68-4.71 (m, 1H), 3.72 (dd, J=10.8 Hz, 3.4 Hz, 1H), 3.64 (dd, J=10.8 Hz, 5.2 Hz, 1H), 3.46 (t, J=7.2 Hz, 1H), 3.32 (t, J=8.7 Hz, 1H), 3.19 (t, J=9.4 Hz, 1H), 2.17-2.25 (m, 1H), 1.64-1.75 (m, 2H).

To a solution of (3aR,4R,5R,6R,7aS)-4,5-dihydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (2.99 g, 14.7 mmol) in DMF (10 mL) at room temperature was added p-toluenesulfonic acid monohydrate (210 mg, 1.10 mmol) followed by benzaldehyde dimethylacetal (6.72 g, 44.2 mmol). The mixture was heated at 60° C. under slightly diminished pressure for 3.5 h. After cooling, the reaction was diluted with water (100 mL) and extracted with EtOAc (2×60 mL). The extracts were washed with brine and dried with MgSO₄. The solvent was evaporated to give the crude product. This was purified by silica gel column, eluted with 10-30% EtOAc in hexanes to provide (3aR,4R,4aR,8aR,9aS)-4-hydroxy-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (3.33 g, 55%). MS m/z 434.6 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.51 (m, 10H), 6.20 (s, 1H), 5.52 (s, 1H), 4.47-4.50 (m, 1H), 4.24 (dd, J=11.1 Hz, 4.7 Hz, 1H), 4.17 (d, J=2.5 Hz, 1H), 3.83-3.88 (m, 1H), 3.69 (s, 3H), 3.55 (t, J=11.0 Hz, 1H), 3.40 (t, J=10.1 Hz, 1H), 3.26 (t, J=6.8 Hz, 1H), 2.11-2.23 (m, 2H), 1.28-1.36 (m, 1H).

To a solution of (3aR,4R,4aR,8aR,9aS)-4-hydroxy-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (1.77 g, 4.31 mmol) in dry DCM (25 mL) at room temperature was added bis(2-methoxyethyl)aminosulfur trifluoride (3.81 g, 17.2 mmol). The mixture was stirred at room temperature under N₂ for 20 h. The mixture was slowly diluted with saturated aqueous NaHCO₃ (80 mL), extracted with EtOAc (2×50 mL). The extracts were washed with brine and dried with MgSO₄. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 25-35% EtOAc in hexanes to give (3aS,4S,4aR,8aR,9aS)-4-fluoro-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (900 mg, 51%). MS m/z 436.6 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.34-7.50 (m, 10H), 6.15 (s, 1H), 5.49 (s, 1H), 4.91 (dd, J=51.4 Hz, 3.0 Hz, 1H), 4.40 (d, J=5.0 Hz, 1H), 4.29 (dd, J=11.2 Hz, 4.8 Hz, 1H), 3.66 (s, 3H), 3.25-3.55 (m, 3H), 2.59-2.71 (m, 1H), 2.20-2.25 (m, 1H), 1.23-1.32 (m, 1H).

A mixture of (3aS,4S,4aR,8aR,9aS)-4-fluoro-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (1.502 g, 3.637 mmol) in 80% acetic acid (40 mL) was heated at 60° C. for 4 h. The solvents were evaporated to give the crude product which was purified by silica gel column, eluted with 10%45% MeOH in DCM to give the product (3aS,4S,4aR,8aR,9aS)-4-fluoro-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (704 mg, 93%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.70-4.73 (m, 1H), 4.69 (ddd, J=52.7 Hz, 3.7 Hz, 1.7 Hz, 1H), 4.87 (ddd, J=22.9 Hz, 6.3 Hz, 3.8 Hz, 1H), 3.74 (d, J=4.6 Hz, 2H), 3.55 (ddd, J=30.1 Hz, 10.7 Hz, 1.4 Hz, 1H), 2.28-2.33 (m, 1H), 2.07-2.16 (m, 1H), 1.72-1.80 (m, 1H).

A mixture of (3aS,4S,5R,6R,7aS)-4-fluoro-5-hydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (704 mg, 3.43 mmol) and LiOH (2.71 g, 113 mmol) in water (35 mL) and MeOH (26 mL) was stirred at reflux for 2 h. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 20%-30% 2 M NH₃ MeOH solution in DCM give (1S,2S,3S,4R,5R)-2-amino-3-fluoro-5-(hydroxymethyl)cyclohexane-1,4-diol (485 mg, 80%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.74 (d, J=52.0 Hz, 1H), 3.96-3.99 (m, 1H), 3.65-3.73 (m, 2H), 3.49 (ddd, J=28.0 Hz, 10.5 Hz, 1.6 Hz, 1H), 3.05 (d, J=31.0 Hz, 1H), 2.09-2.19 (m, 1H), 1.96 (dt, J=14.5 Hz, 3.7 Hz, 1H), 1.46-1.53 (m, 1H).

To a solution of (1S,2S,3S,4R,5R)-2-amino-3-fluoro-5-(hydroxymethyl)cyclohexane-1,4-diol (480 mg, 2.68 mmol) in DMF (5 mL) at room temperature was added thiocarbonyldiimidazole (549 mg, 3.08 mmol). The mixture was stirred at room temperature for 1.5 h. Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 10%-35 MeOH in DCM to give the product (3aS,4S,5R,6R,7aS)-4-fluoro-5-hydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazole-2(3H)-thione (494 mg, 83%) as a pale yellow solid. ¹H NMR (500 MHz, MeOD) δ 4.74-4.77 (m, 1H), 4.56 (ddd, J=52.8 Hz, 3.8 Hz, 1.7 Hz, 1H), 3.98 (ddd, J=23.3 Hz, 7.0 Hz, 3.9 Hz, 1H), 3.59-3.64 (m, 2H), 3.45 (ddd, J=29.6 Hz, 10.6 Hz, 1.5 Hz, 1H), 2.22-2.27 (m, 1H), 1.95-2.02 (m, 1H), 1.69-1.75 (m, 1H).

To a solution of (3aS,4S,5R,6R,7aS)-4-fluoro-5-hydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazole-2(3H)-thione (490 mg, 2.22 mmol) in EtOH (8 mL) was added MeI (630 mg, 4.43 mmol) and 5 N NaOH (0.58 mL, 2.9 mmol). The mixture was stirred at room temperature for 2 h. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 10%-20% MeOH in DCM to give (3aS,4S,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylthio)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (370 mg, 71%) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 4.78 (ddd, J=52.1 Hz, 3.8 Hz, 1.6 Hz, 1H), 4.64-4.68 (m, 1H), 4.03 (ddd, J=25.8 Hz, 7.6 Hz, 3.9 Hz, 1H), 3.91 (dd, J=10.9 Hz, 3.7 Hz, 1H), 3.61-3.71 (m, 2H), 2.48 (s, 3H), 2.17-2.30 (m, 2H), 1.95-2.02 (m, 1H), 1.65-1.72 (m, 1H).

To a solution of (3 aS,4S,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylthio)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (50 mg, 0.21 mmol) in EtOH (3 mL) was added azetidine hydrochloride (100 mg, 1.06 mmol). The mixture was heated at reflux for 17 h. After cooling, solid NaHCO₃ (100 mg, 1.19 mmol) was added and stirred for 10 min. Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 5%-10% 2 M NH₃ MeOH solution in DCM to give the product (3aS,4S,5R,6R,7aS)-2-(azetidin-1-yl)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (31.4 mg, 60%) as a white solid. MS m/z 245.1 (M+1, 100%); ¹H NMR (400 MHz, MeOD) δ 4.57-4.61 (m, 1H), 4.58 (ddd, J=52.8 Hz, 3.7 Hz, 1.6 Hz, 1H), 4.02 (t, J=7.6 Hz, 4H), 3.85 (ddd, J=26.1 Hz, 7.1 Hz, 3.8 Hz, 1H), 3.66-3.73 (m, 2H), 3.49 (ddd, J=30.2 Hz, 10.0 Hz, 1.5 Hz, 1H), 2.27-2.38 (m, 3H), 2.01-2.09 (m, 1H), 1.73-1.81 (m, 1H); ¹³C NMR (100 MHz, MeOD) δ 165.85, 93.17 (d, J=178.6 Hz), 80.71, 70.65 (d, J=19.1 Hz), 64.45 (d, J=17.3 Hz), 63.94, 51.87, 35.47 (d, J=5.8 Hz), 28.39, 17.77.

The following examples were synthesized according to procedures analogous to the schemes and examples outlined above.

TABLE 5 Example Structure Name 11

(3aS,4S,5R,6R,7aS)-2-(dimethylamino)-4- fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol ¹H NMR (400 MHz, MeOD) δ 4.60-4.64 (m, 1H), 4.59 (ddd, J = 52.8 Hz, 3.7 Hz, 1.6 Hz, 1H), 3.85 (ddd, J = 25.9 Hz, 6.9 Hz, 3.8 Hz, 1H), 3.66-3.74 (m, 2H), 3.49 (ddd, J = 30.0 Hz, 9.2 Hz, 1.5 Hz, 1H), 2.93 (s, 6H), 2.34 (dt, J = 15.4 Hz, 3.8 Hz, 1H), 2.02-2.11 (m, 1H), 1.73- 1.81 (m, 1H); ¹³C NMR (100 MHz, MeOD) δ 165.73, 93.26 (d, J = 178.4 Hz), 80.86, 70.70 (d, J = 19.1 Hz), 64.08 (d, J = 17.3 Hz), 63.90, 37.66, 35.22 (d, J = 5.9 Hz), 28.40; MS, (ES, m/z) [M + H]⁺ 233.1. 12

(3aS,4S,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol ¹H NMR (400 MHz, MeOD) δ 4.62 (dd, J = 3.6 Hz, 1.4 Hz, 0.5H), 4.49-4.53 (m, 1.5H), 3.77 (ddd, J =26.2 Hz, 7.0 Hz, 3.8 Hz, 1H), 3.61-3.68 (m, 2H), 3.44 (ddd, J = 30.2 Hz, 10.3 Hz, 1.4 Hz, 1H), 2.74 (s, 3H), 2.24 (dt, J = 15.4 Hz, 4.0 Hz, 1H), 1.97-2.05 (m, 1H), 1.67-1.75 (m, 1H); ¹³C NMR (100 MHz, MeOD) δ 165.84, 93.33 (d, J = 178.5 Hz), 79.77, 70.75 (d, J = 19.2 Hz), 63.97, 63.95 (d, J = 17.4 Hz), 35.36 (d, J = 5.8 Hz), 29.11, 28.41; MS, (ES, m/z) [M + H]⁺ 219.1. 13

(3aS,4S,5R,6R,7aS)-2-(ethylamino)-4- fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol ¹H NMR (400 MHz, MeOD) δ 4.63 (dd, J = 3.7 Hz, 1.5 Hz, 0.5H), 4.49-4.54 (m, 1.5H), 3.78 (ddd, J =25.9 Hz, 6.9 Hz, 3.8 Hz, 1H), 3.61-3.69 (m, 2H), 3.45 (ddd, J = 30.0 Hz, 10.4 Hz, 1.5 Hz, 1H), 3.08-3.22 (m, 2H), 2.24 (dt, J = 15.4 Hz, 3.9 Hz, 1H), 1.97-2.06 (m, 1H), 1.67- 1.75 (m, 1H), 1.11 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, MeOD) δ 164.97, 93.31 (d, J = 178.5 Hz), 79.61, 70.72 (d, J = 19.1 Hz), 63.94, 63.64 (d, J = 17.4 Hz), 38.22, 35.27 (d, J = 5.8 Hz), 28.36, 15.11; MS, (ES, m/z) [M + H]⁺ 233.1.

Example 14 (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol

To a solution of (3aS,4R,5R,6R,7aS)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)hexahydrobenzo[d]oxazol-2(3H)-one (7.35 g, 15.5 mmol) in DCM (80 mL) at −78° C. was added a solution of BCl₃ in DCM (1.0 M, 53 mL, 53 mmol). The mixture was slowly warmed up to 0° C. and stirred at this temperature for 4 h. The reaction was cooled to −78° C. again and a 1:1 mixture of MeOH-DCM (50 mL) was added dropwise to quench the reaction. Solvents were evaporated and the residue was treated with MeOH for three more times. The crude product was purified by silica gel column chromatography, eluted with 5%-15% MeOH in DCM to give (3aR,4R,5R,6R,7aS)-4,5-dihydroxy-6-(hydroxymethyl)-hexahydrobenzo[d]oxazol-2(3H)-one (2.99 g, 95%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.68-4.71 (m, 1H), 3.72 (dd, J=10.8 Hz, 3.4 Hz, 1H), 3.64 (dd, J=10.8 Hz, 5.2 Hz, 1H), 3.46 (t, J=7.2 Hz, 1H), 3.32 (t, J=8.7 Hz, 1H), 3.19 (t, J=9.4 Hz, 1H), 2.17-2.25 (m, 1H), 1.64-1.75 (m, 2H).

To a solution of the above material (2.99 g, 14.7 mmol) in DMF (10 mL) at room temperature was added p-toluenesulfonic acid monohydrate (210 mg, 1.10 mmol) followed by benzaldehyde dimethylacetal (6.72 g, 44.2 mmol). The mixture was heated at 60° C. under slightly diminished pressure for 3.5 h. After cooling, the reaction was diluted with water (100 mL) and extracted with EtOAc (2×60 mL). The extracts were washed with brine and dried with MgSO₄. The solvent was evaporated to give the crude product. This was purified by silica gel column, eluted with 10-30% EtOAc in hexanes to provide (3aR,4R,4aR,8aR,9aS)-4-hydroxy-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (3.33 g, 55%). MS m/z 434.6 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.51 (m, 10H), 6.20 (s, 1H), 5.52 (s, 1H), 4.47-4.50 (m, 1H), 4.24 (dd, J=11.1 Hz, 4.7 Hz, 1H), 4.17 (d, J=2.5 Hz, 1H), 3.83-3.88 (m, 1H), 3.69 (s, 3H), 3.55 (t, J=11.0 Hz, 1H), 3.40 (t, J=10.1 Hz, 1H), 3.26 (t, J=6.8 Hz, 1H), 2.11-2.23 (m, 2H), 1.28-1.36 (m, 1H).

To a solution of the above material (1.77 g, 4.31 mmol) in dry DCM (25 mL) at room temperature was added bis(2-methoxyethyl)aminosulfur trifluoride (3.81 g, 17.2 mmol). The mixture was stirred at room temperature under N₂ for 20 h. The mixture was slowly diluted with saturated aqueous NaHCO₃ (80 mL), extracted with EtOAc (2×). The extracts were washed with brine and dried with MgSO₄. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 25-35% EtOAc in hexanes to give (3aS,4S,4aR,8aR,9aS)-4-fluoro-3-(methoxy(phenyl)methyl)-6-phenyloctahydro-2H-[1,3]dioxino[5′,′:4,5]benzo[1,2-d]oxazol-2-one (900 mg, 51%). MS m/z 436.6 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 7.34-7.50 (m, 10H), 6.15 (s, 1H), 5.49 (s, 1H), 4.91 (dd, J=51.4 Hz, 3.0 Hz, 1H), 4.40 (d, J=5.0 Hz, 1H), 4.29 (dd, J=11.2 Hz, 4.8 Hz, 1H), 3.66 (s, 3H), 3.25-3.55 (m, 3H), 2.59-2.71 (m, 1H), 2.20-2.25 (m, 1H), 1.23-1.32 (m, 1H).

A mixture of the above material (1.502 g, 3.637 mmol) in 80% acetic acid (40 mL) was heated at 60° C. for 4 h. The solvents were evaporated to give the crude product which was purified by silica gel column, eluted with 10%45% MeOH in DCM to give the product (3aS,4S,5R,6R,7aS)-4-fluoro-5-hydroxy-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (704 mg, 93%) as a white solid. ¹H NMR (400 MHz, MeOD) δ 4.70-4.73 (m, 1H), 4.69 (ddd, J=52.7 Hz, 3.7 Hz, 1.7 Hz, 1H), 4.87 (ddd, J=22.9 Hz, 6.3 Hz, 3.8 Hz, 1H), 3.74 (d, J=4.6 Hz, 2H), 3.55 (ddd, J=30.1 Hz, 10.7 Hz, 1.4 Hz, 1H), 2.28-2.33 (m, 1H), 2.07-2.16 (m, 1H), 1.72-1.80 (m, 1H).

To a solution of the above material (410 mg, 1.00 mmol) in anhydrous DMF (8 mL) was added imidazole (544 mg, 8.00 mmol) followed by TBDMSCl (962 mg, 5.20 mmol). The reaction was stirred at room temperature for 5 h. The mixture was diluted with water (60 mL) and extracted with EtOAc (2×30 mL). The extracts were washed brine and dried over anhydrous MgSO₄. The solvent was evaporated under reduced pressure to give pale yellow syrup. This was purified on silica gel column, eluted with 20%-30% EtOAc in hexane to give (3aS,4S,5R,6R,7aS)-5-((tert-butyldimethylsilyl)oxy)-6-(((tert-butyldimethylsilyl)oxy)methyl)-4-fluorohexahydrobenzo[d]oxazol-2(3H)-one (611 mg, 71%) as a white solid. MS m/z 456.3 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) 5.01 (s, 1H), 4.80 (m, 1H), 4.53 (ddd, J=49.6 Hz, 4.1 Hz, 2.4 Hz, 1H), 3.85 (ddd, J=16.1 Hz, 7.1 Hz, 4.1 Hz, 1H), 3.81 (dd, J=10.1 Hz, 3.4 Hz, 1H), 3.78 (ddd, J=27.4 Hz, 7.4 Hz, 2.2 Hz, 1H), 3.56 (dd, J=9.9 Hz, 2.5 Hz, 1H), 2.21-2.15 (m, 2H), 1.76 (ddd, J=16.6 Hz, 12.3 Hz, 4.2 Hz, 1H), 0.90 (s, 9H), 0.89 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H), 0.05 (s, 6H).

A solution of the above material (456 mg, 1.05 mmol) in 7:3 methanol-acetic acid solution (10 mL) was heated at 60° C. for 16 h. The solvents were evaporated under reduced pressure. The residue was purified on silica gel column, eluted with 30-70% EtOAc in hexane and 15% methanol in DCM to give (3aS,4S,5R,6R,7aS)-5-((tert-butyldimethylsilyl)oxy)-4-fluoro-6-(hydroxymethyl)hexahydrobenzo[d]oxazol-2(3H)-one (250 mg, 71%). MS m/z 342.1 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) 5.66 (s, 1H), 4.74 (ddd, J=6.4 Hz, 4.6 Hz, 2.3 Hz, 1H), 4.58 (ddd, J=51.0 Hz, 3.8 Hz, 1.9 Hz, 1H), 3.79 (dd, J=10.4 Hz, 3.6 Hz, 1H), 3.78-3.70 (m, 2H), 3.65 (dd, J=10.6 Hz, 3.8 Hz, 1H), 2.30-2.24 (m, 2H), 1.88 (brs, 1H), 1.73 (ddd, J=16.8 Hz, 13.1 Hz, 4.4 Hz, 1H), 0.90 (s, 9H), 0.10 (s, 6H).

To a solution of the above material (263 mg, 0.824 mmol) in dry DCM (7 mL) at 0° C. was added DMP (524 mg, 1.237 mmol). The mixture was stirred at room temperature for 2 h. Aqueous saturated NaHCO₃ and 1 M Na₂S₂O₃ (5 mL) were added and stirred for 10 min. Layers were separated. The aqueous was extracted with diethyl ether (2×20 mL). The combined organic solution was washed brine and dried over MgSO₄. The solvents were evaporated under reduced pressure. The residue was purified on silica gel column, eluted with 2:3:4 DCM-hexane-EtOAc to give (3aS,4S,5R,6S,7aS)-5-((tert-butyldimethylsilyl)oxy)-4-fluoro-2-oxooctahydrobenzo[d]oxazole-6-carbaldehyde (198 mg, 76%). MS m/z 340.1 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 9.91 (s, 1H), 5.26 (s, 1H), 4.79-4.75 (m, 1H), 4.54 (ddd, J=49.8 Hz, 3.9 Hz, 2.2 Hz, 1H), 4.04 (ddd, J=22.3 Hz, 8.6 Hz, 2.1 Hz, 1H), 3.86 (ddd, J=17.6 Hz, 6.8 Hz, 3.9 Hz, 1H), 3.28-3.22 (m, 1H), 2.39 (dt, J=15.8 Hz, 4.0 Hz, 1H), 1.85 (ddd, J=16.0 Hz, 11.6 Hz, 4.4 Hz, 1H), 0.89 (s, 9H), 0.11 (s, 3H), 0.07 (s, 3H).

To a solution of acetyl chloride (410 mg, 5.22 mmol) in anhydrous DCM (3 mL) was added a solution of DIPEA (673 mg, 5.22 mmol) in anhydrous DCM (3 mL). The mixture was then added to a 0° C. solution of the above material (827 mg, 2.61 mmol) in anhydrous DCM (10 mL). The reaction was slowly warmed up to room temperature and stirred for 2 h. The mixture was diluted with aqueous NH₄Cl (100 mL) and extracted with DCM (2×30 mL). The extracts were washed brine and dried over anhydrous MgSO₄. The solvent was evaporated under reduced pressure to give the crude (3aS,4S,5R,6S,7aS)-3-acetyl-5-((tert-butyldimethylsilyl)oxy)-4-fluoro-2-oxooctahydrobenzo[d]oxazole-6-carbaldehyde (937 mg, 100%), which was pure enough for next reaction. MS m/z 382.2 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) 9.95 (s, 1H), 4.48 (ddd, J=51.4 Hz, 3.6 Hz, 1.6 Hz, 1H), 4.64-4.60 (m, 1H), 4.47 (ddd, J=22.4 Hz, 6.2 Hz, 3.7 Hz, 1H), 3.83 (ddd, J=27.7 Hz, 10.6 Hz, 1.6 Hz, 1H), 3.28-3.21 (m, 1H), 2.54 (s, 3H), 2.39 (ddd, J=16.3 Hz, 4.1 Hz, 2.2 Hz, 1H), 1.90 (ddd, J=16.6 Hz, 12.4 Hz, 4.6 Hz, 1H), 0.87 (s, 9H), 0.10 (s, 3H), 0.05 (s, 3H).

To a solution of the above material (937 mg, 2.61 mmol) in dry DCM (15 mL) at 0° C. was added bis(2-methoxyethyl)aminosulfur trifluoride (50% in THF, 4.52 mL, 10.4 mmol). The mixture was stirred at room temperature under N₂ for 17 h. The mixture was slowly diluted with saturated aqueous NaHCO₃ (80 mL) and extracted with DCM (2×40 mL). The extracts were washed with brine and dried with MgSO₄. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 15-20% EtOAc in hexane to give (3aS,4S,5R,6S,7aS)-3-acetyl-5-((tert-butyldimethylsilyl)oxy)-6-(difluoromethyl)-4-fluorohexahydrobenzo[d]oxazol-2(3H)-one (798 mg, 80%). MS m/z 404.2 (M+23, 100%); ¹H NMR (400 MHz, CDCl₃) δ 6.11 (td, J=55.8 Hz, 1.4 Hz, 1H), 4.97 (dm, J=51.3 Hz, 1H), 4.68-4.65 (m, 1H), 4.47 (ddd, J=22.3 Hz, 6.2 Hz, 3.8 Hz, 1H), 3.67 (dd, J=27.8 Hz, 10.7 Hz, 1H), 2.72-2.55 (m, 1H), 2.55 (s, 3H), 2.51 (ddd, J=16.1 Hz, 3.8 Hz, 2.0 Hz, 1H), 1.84 (ddd, J=16.7 Hz, 12.7 Hz, 4.6 Hz, 1H), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H).

To a solution of the above material (309 mg, 0.811 mmol) in MeOH (16 mL) and water (8 mL) was added LiOH (292 mg, 12.2 mmol). The mixture was heated at refluxing temperature for 20 h. Solvents were evaporated and the residue was purified by silica gel column chromatography, eluted with 10%-30% 1.8 N NH₃-MeOH in DCM to give the product (1S,2S,3S,4R,5S)-2-amino-5-(difluoromethyl)-3-fluorocyclohexane-1,4-diol (104 mg, 65%). ¹H NMR (400 MHz, CD₃OD) δ 6.18 (td, J=56.9 Hz, 1.4 Hz, 1H), 4.70 (dd, J=51.9 Hz, 1.7 Hz, 1H), 3.98 (dd, J=6.1 Hz, 3.0 Hz, 1H), 3.60 (ddd, J=28.4 Hz, 11.2 Hz, 1.3 Hz, 1H), 2.82 (ddd, J=33.4 Hz, 3.5 Hz, 2.6 Hz, 1H), 2.60-2.45 (m, 1H), 2.05 (dt, J=14.4 Hz, 6.8 Hz, 1H), 1.55 (ddd, J=15.1 Hz, 13.0 Hz, 2.7 Hz, 1H).

To a solution of the above material (101.2 mg, 0.509 mmol) in DMF (3 mL) at room temperature was added thiocarbonyldiimidazole (109 mg, 0.610 mmol). The mixture was stirred at room temperature for 6 h. Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 5%-10% 1.8 N NH₃-MeOH in DCM to give (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-5-hydroxyhexahydrobenzo[d]oxazole-2(3H)-thione (81.9 mg, 67%). ¹H NMR (400 MHz, MeOD) δ 6.21 (td, J=56.5 Hz, 1.6 Hz, 1H), 4.91 (ddd, J=7.0 Hz, 4.8 Hz, 2.1 Hz, 1H), 4.69 (dm, J=52.2 Hz, 1H), 4.12 (ddd, J=23.4 Hz, 6.9 Hz, 3.8 Hz, 1H), 3.66 (dd, J=28.7 Hz, 10.6 Hz, 1H), 2.55-2.45 (m, 1H), 2.43 (ddd, J=15.5 Hz, 4.4 Hz, 2.4 Hz, 1H), 1.98 (ddd, J=16.6 Hz, 12.4 Hz, 4.8 Hz, 1H).

To a solution of the above material (81.9 mg, 0.340 mmol) in MeOH (4 mL) was added MeI (96.5 mg, 0.680 mmol) and 5 N NaOH (100 mg, 0.51 mmol). The mixture was stirred at room temperature for 1 h. The solvents were evaporated to give the crude product. This was purified by SiO₂ column, eluted with 60%-70% EtOAc in hexane to give (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-2-(methylthio)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (86.7 mg, 100%) as a pale yellow solid. MS m/z 256.1 (M+1, 100%); ¹H NMR (400 MHz, CDCl₃) δ 6.14 (td, J=56.3 Hz, 1.8 Hz, 1H), 4.83 (dm, J=52.3 Hz, 1H), 4.78-4.74 (m. 1H), 4.14 (ddd, J=25.0 Hz, 8.0 Hz, 3.8 Hz, 1H), 3.73 (dd, J=25.6 Hz, 8.9 Hz, 1H), 2.51 (s, 3H), 2.44-2.37 (m, 2H), 1.92 (ddd, J=15.9 Hz, 10.7 Hz, 4.9 Hz, 1H).

To a solution of the above material (44.3 mg, 0.174 mmol) in EtOH (3 mL) was added methylamine hydrochloride (67.5 mg, 0.521 mmol). The mixture was heated at reflux for 16 h. Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 65% EtOAc in hexane and then 10% 1.8 M NH₃ MeOH solution in DCM to give (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (15.1 mg, 37%). MS m/z 239.1 (M+1, 100%); ¹H NMR (500 MHz, MeOD) δ 6.16 (td, J=56.6 Hz, 1.4 Hz, 1H), 4.74 (brs, 1H), 4.65 (dm, J=52.3 Hz, 1H), 4.00 (ddd, J=25.1 Hz, 6.8 Hz, 3.8 Hz, 1H), 3.64 (dd, J=29.2 Hz, 10.4 Hz, 1H), 2.83 (s, 3H), 2.47-2.37 (m, 1H), 2.35 (dt, J=15.7 Hz, 3.81 Hz, 1H), 1.95 (ddd, J=16.0 Hz, 11.4 Hz, 4.9 Hz, 1H); ¹³C NMR (100 MHz, MeOD) δ 165.54, 118.17 (t, J=238.5 Hz), 92.70 (d, J=179.7 Hz), 79.84, 68.60 (dd, J=18.8 Hz, 8.3 Hz), 61.96 (d, J=17.0 Hz), 37.57 (td, J=19.3 Hz, 6.8 Hz), 29.09, 22.22 (t, J=4.5 Hz).

Example 15 (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-4-fluoro-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol

To a solution of (3 aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-2-(methylthio)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (46.5 mg, 0.182 mmol) in EtOH (3 mL) was added azetidine hydrochloride (51.2 mg, 0.547 mmol). The mixture was heated at reflux for 9 h. Solvent was evaporated and the residue was purified by silica gel column chromatography, eluted with 65% EtOAc in hexane and then 10% 1.8 M NH₃ MeOH solution in DCM to give (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-4-fluoro-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol (37.2 mg, 77%). MS m/z 265.1 (M+1, 100%); ¹H NMR (500 MHz, MeOD) δ 6.16 (td, J=56.7 Hz, 1.8 Hz, 1H), 4.63-4.59 (m, 1H), 4.60 (dm, J=52.5 Hz, 1H), 4.03 (t, J=7.6 Hz, 4H), 3.88 (ddd, J=26.3 Hz, 7.1 Hz, 3.8 Hz, 1H), 3.61 (dd, J=29.4 Hz, 10.2 Hz, 1H), 2.45-2.30 (m, 4H), 1.94 (ddd, J=15.8 Hz, 10.8 Hz, 5.2 Hz, 1H); ¹³C NMR (100 MHz, MeOD) δ 165.68, 118.32 (t, J=238.5 Hz), 92.92 (d, J=179.3 Hz), 79.59, 68.84 (dd, J=18.8 Hz, 8.7 Hz), 64.22 (d, J=17.3 Hz), 51.87, 37.90 (td, J=19.7 Hz, 6.7 Hz), 22.41 (t, J=4.5 Hz), 17.77.

The following examples may be synthesized according to procedures analogous to the schemes and examples outlined above.

TABLE 6 Example Name Structure 16 (3aR,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

17 (3aR,4R,5S,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

18 (3aR,4S,5S,6S,7aS)-2-(azetidin-1-yl)-6- (difluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

19 (3aS,4R,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

20 (3aS,4R,5S,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

21 (3aS,4S,5S,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

22 (3aR,5S,6R,7aS)-2-(azetidin-1-yl)-6- (hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

23 (3aR,5R,6R,7aS)-2-(azetidin-1-yl)-6- (hydroxymethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

24 (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6- methyl-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

25 (3aR,4S,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]thiazol- 5-ol

26 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(methylamino)-3a,4,5,6,7,7a- hexahydrobenzo[d]thiazole-4,5-diol

27 (3aS,4S,5R,6R,7aS)-4-fluoro-6- (hydroxymethyl)-2-(pyrrolidin-1-yl)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

28 (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)- 2-(pyrrolidin-1-yl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazole-4,5-diol

29 (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-4- fluoro-6-(fluoromethyl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

30 (3aS,4S,5R,6S,7aS)-4-fluoro-6- (fluoromethyl)-2-(methylamino)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

31 (3aS,4S,5R,6S,7aS)-4-fluoro-6- (fluoromethyl)-2-(pyrrolidin-1-yl)- 3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol- 5-ol

32 (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)- 4-fluoro-2-(pyrrolidin-1-yl)-3a,4,5,6,7,7a- hexahydrobenzo[d]oxazol-5-ol

Biological Activity

Assay for Determination of K_(I) Values for Inhibition of O-GlcNAcase Activity

Experimental Procedure for Kinetic Analyses:

Enzymatic reactions were carried out in a reaction containing 50 mM NaH₂PO₄, 100 mM NaCl and 0.1% BSA (pH 7.0) using 2 mM 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide dihydrate (Sigma M2133) dissolved in ddH₂O, as a substrate. The amount of purified human O-GlcNAcase enzyme used in the reaction was 0.7 nM. Test compound of varying concentrations was added to the enzyme prior to initiation of the reaction. The reaction was performed at room temperature in a 96-well plate and was initiated with the addition of substrate. The production of fluorescent product was measured every 60 sec for 45 min with a Tecan Infinite M200 plate-reader with excitation at 355 nM and emission detected at 460 nM, with 4-Methylumbelliferone (Sigma M1381) used to produce a standard curve. The slope of product production was determined for each concentration of compound tested and plotted, using standard curve fitting algorithms for sigmoidal dose response curves. The values for a four parameter logistic curve fit of the data were determined.

K_(I) values were determined using the Cheng-Prusoff equation; the K_(m) of O-GlcNAcase for substrate was 0.2 mM.

Examples 1 to 15 were tested in the above described assay and exhibited K_(I) values for inhibition of O-GlcNAcase in the range 0.1 nM-10 μM.

Assay for Determination of K_(I) Values for Inhibition of β-Hexosaminidase Activity

Experimental Procedure for Kinetic Analyses:

Enzymatic reactions were carried out in a reaction containing 50 mM NaH₂PO₄, 100 mM NaCl and 0.1% BSA (pH 7.0) using 2 mM 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide dihydrate (Sigma M2133) dissolved in ddH₂O, as a substrate. The amount of purified human β-hexosaminidase enzyme used in the reaction was 24 nM. Test compound of varying concentrations was added to the enzyme prior to initiation of the reaction. The reaction was performed at room temperature in a 96-well plate and was initiated with the addition of substrate. The production of fluorescent product was measured every 60 sec for 45 min with a Tecan Infinite M200 plate-reader with excitation at 355 nM and emission detected at 460 nM, with 4-Methylumbelliferone (Sigma M1381) used to produce a standard curve. The slope of product production was determined for each concentration of compound tested and plotted, using standard curve fitting algorithms for sigmoidal dose response curves. The values for a four parameter logistic curve fit of the data were determined.

K_(I) values were determined using the Cheng-Prusoff equation.

When tested in this assay, many of the compounds described herein exhibit K_(I) values for inhibition of β-hexosaminidase in the range 10 nM to greater than 100 uM.

The selectivity ratio for inhibition of O-GlcNAcase over β-hexosaminidase is defined here as:

K_(I)(β-hexosaminidase)/K_(I)(O-GlcNAcase)

In general, the compounds described herein exhibited a selectivity ratio in the range of about 10 to 100000. Thus, many compounds of the invention exhibit high selectivity for inhibition of O-GlcNAcase over β-hexosaminidase.

Assay for Determination of Cellular Activity for Compounds that Inhibit O-GlcNAcase Activity

Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An increase in O-GlcNAcylated protein can be measured by an antibody, such as RL-2, that binds to O-GlcNAcylated protein. The amount of O-GlcNAcylated protein:RL2 antibody interaction can be measured by enzyme linked immunosorbant assay (ELISA) procedures.

A variety of tissue culture cell lines, expressing endogenous levels of O-GlcNAcase, can be utilized; examples include rat PC-12, and human U-87, or SK-N-SH cells. In this assay, rat PC-12 cells were plated in 96-well plates with approximately 10,000 cells/well. Compounds to be tested were dissolved in DMSO, either 2 or 10 mM stock solution, and then diluted with DMSO and water in a two-step process using a Tecan workstation. Cells were treated with diluted compounds for 24 h (5.4 μL into 200 μL l well volume) to reach a final concentration of inhibitor desired to measure a compound concentration dependent response, typically, ten 3 fold dilution steps, starting at 10 μM were used to determine a concentration response curve. To prepare a cell lysate, the media from compound treated cells was removed, the cells were washed once with phosphate buffered saline (PBS) and then lysed for 5 minutes at room temperature in 50 μL of Phosphosafe reagent (Novagen Inc, Madison, Wis.) with protease inhibitors and PMSF. The cell lysate was collected and transferred to a new plate, which was then either coated to assay plates directly or frozen −80° C. until used in the ELISA procedure. If desired, the total protein concentration of samples was determined using 20 μL of the sample using the BCA method.

The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 μL/well of the cell lysate (1:10 dilution of the lysate with PBS containing protease inhibitors, phosphatase inhibitors, and PMSF). The following day the wells were washed 3 times with 300 μL/well of Wash buffer (Tris-buffered saline with 0.1% Tween 20). The wells were blocked with 100 μL/well Blocking buffer (Tris buffered saline w/0.05% Tween 20 and 2.5% Bovine serum albumin) Each well was then washed two times with 300 μL/well of wash buffer. The anti O-GlcNAc antibody RL-2 (Abcam, Cambridge, Mass.), diluted 1:1000 in blocking buffer, was added at 100 μL/well. The plate was sealed and incubated at 37° C. for 2 h with gentle shaking. The wells were then washed 3-times with 300 μL/well wash buffer. To detect the amount of RL-2 bound horse-radish peroxidase (HRP) conjugated goat anti-mouse secondary antibody (diluted 1:3000 in blocking buffer) was added at 100 μL/well. The plate was incubated for 60 min at 37° C. with gentle shaking. Each well was then washed 3-times with 300 μL/well wash buffer. The detection reagent was added, 100 μL/well of Amplex Ultra RED reagent (prepared by adding 30 μL of 10 mM Amplex Ultra Red stock solution to 10 mL PBS with 18 μL 3% hydrogen peroxide, H₂O₂). The detection reaction was incubated for 15 minutes at room temperature and then read with excitation at 530 nm and emission at 590 nm.

The amount of O-GlcNAcylated protein, as detected by the ELISA assay, was plotted for each concentration of test compound using standard curve fitting algorithms for sigmoidal dose response curves. The values for a four parameter logistic curve fit of the data were determined, with the inflection point of the curve being the potency value for the test compound.

Assay for Determination of Apparent Permeability (P_(app))

Bi-directional transport was evaluated in LLC-PK1 cells in order to determine apparent permeability (P_(app)). LLC-PK1 cells can form a tight monolayer and therefore can be used to assess vectorial transport of compounds from basolateral to apical (B→A) and from apical to basolateral (A→B).

To determine P_(app), LLC-PK1 cells were cultured in 96-well transwell culture plates (Millipore). Solutions containing the test compounds (1 μM) were prepared in Hank's Balanced Salt Solution with 10 mM HEPES. Substrate solution (150 μL) was added to either the apical (A) or the basolateral (B) compartment of the culture plate, and buffer (150 μL) was added to the compartment opposite to that containing the compound. At t=3 h, 50 μL samples were removed from both sides of monolayers dosed with test compound and placed in 96 well plates, scintillant (200 μL) or internal standard (100 μL labetolol 1 μM) was added to the samples and concentration was determined by liquid scintillation counting in a MicroBeta Wallac Trilux scintillation counter (Perkin Elmer Life Sciences, Boston, Mass.) or by LCMS/MS (Applied Biosystems SCIEX API 5000 triple quadruple mass spectrometer). [³H]Verapamil (1 μM) was used as the positive control. The experiment was performed in triplicate.

The apparent permeability, P_(app), was calculated by the following formula for samples taken at t=3 h:

$P_{app} = {\frac{{Volume}\mspace{14mu} {of}\mspace{14mu} {Receptor}\mspace{14mu} {Chamber}\; ({mL})}{\left\lbrack {{Area}\mspace{14mu} {of}\mspace{14mu} {membrance}\; \left( {cm}^{2} \right)} \right\rbrack \left\lbrack {{Initial}\mspace{14mu} {Concentration}\; \left( {\mu \; M} \right)} \right\rbrack} \times \frac{\Delta \mspace{14mu} {in}\mspace{14mu} {Concentration}\; \left( {\mu \; M} \right)}{\Delta \mspace{14mu} {in}\mspace{14mu} {Time}\; (s)}}$

Where: Volume of Receptor Chamber was 0.15 mL; Area of membrane was 0.11 cm²; the Initial Concentration is the sum of the concentration measured in the donor plus concentration measured in receiver compartments at t=3 h; Δ in Concentration is concentration in the receiver compartment at 3 h; and Δ in Time is the incubation time (3×60×60=10800 s). P_(app) was expressed as 10⁻⁶ cm/s. The P_(app) (LLC-PK1 cells) are the average of the P_(app) for transport from A to B and P_(app) for transport from B to A at t=3 h:

${P_{app}\left( {{LLC} - {{PK}\; 1\mspace{14mu} {Cells}}} \right)} = \frac{{P_{app}\left( A\rightarrow B \right)} + {P_{app}\left( B\rightarrow A \right)}}{2}$

Representative data from the binding, cell-based, and permeability assays described above are shown in the following table. Certain compounds of the invention exhibited superior potency or permeability in one or more of these assays.

TABLE 7 Cell-based Fluorescence- Papp LLC-PK1 ELISA based hOGA cells Example Structure EC₅₀ (nM) Ki (nM) (10⁻⁶ cm/s) 2

8.8 3.0 6.5 4

5.2 1.1 5.1 6

5.1 0.7 2.8 8

4.7 1.4 2.7 10 

ND 7.0 ND 12 

ND 8.6 2.2 15 

ND 20.5  6.5

The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.

REFERENCES

-   1. C. R. Tones, G. W. Hart, J Biol Chem 1984, 259, 3308-17. -   2. R. S. Haltiwanger, G. D. Holt, and G. W. Hart, J Biol Chem 1990,     265, 2563-8. -   3. L. K. Kreppel, M. A. Blomberg, and G. W. Hart, J Biol Chem 1997,     272, 9308-15. -   4. W. A. Lubas, et al., J Biol Chem 1997, 272, 9316-24. -   5. W. A. Lubas, J. A. Hanover, J Biol Chem 2000, 275, 10983-8. -   6. D. L. Dong, G. W. Hart, J Biol Chem 1994, 269, 19321-30. -   7. Y. Gao, et al., J Biol Chem 2001, 276, 9838-45. -   8. E. P. Roquemore, et al., Biochemistry 1996, 35, 3578-86. -   9. S. P. Jackson, R. Tjian, Cell 1988, 55, 125-33. -   10. W. G. Kelly, M. E. Dahmus, and G. W. Hart, J Biol Chem 1993,     268, 10416-24. -   11. M. D. Roos, et al., Mol Cell Biol 1997, 17, 6472-80. -   12. N. Lamarre-Vincent, L. C. Hsieh-Wilson, J Am Chem Soc 2003, 125,     6612-3. -   13. F. Zhang, et al., Cell 2003, 115, 715-25. -   14. K. Vosseller, et al., Proc Natl Acad Sci USA 2002, 99, 5313-8. -   15. W. A. Lubas, et al., Biochemistry 1995, 34, 1686-94. -   16. L. S. Griffith, B. Schmitz, Biochem Biophys Res Commun 1995,     213, 424-31. -   17. R. N. Cole, G. W. Hart, J Neurochem 1999, 73, 418-28. -   18.1. Braidman, et al., Biochem J1974, 143, 295-301. -   19. R. Ueno, C. S. Yuan, Biochim Biophys Acta 1991, 1074, 79-84. -   20. C. Toleman, et al., J Biol Chem 2004, 279, 53665-73. -   21. F. Liu, et al., Proc Nall Acad Sci USA 2004, 101, 10804-9. -   22. T. Y. Chou, G. W. Hart, Adv Exp Med Biol 2001, 491, 413-8. -   23. M. Goedert, et al., Neuron 1992, 8, 159-68. -   24. M. Goedert, et al., Neuron 1989, 3, 519-26. -   25. E. Kopke, et al., J Biol Chem 1993, 268, 24374-84. -   26. H. Ksiezak-Reding, W. K. Liu, and S. H. Yen, Brain Res 1992,     597, 209-19. -   27. P. V. Arriagada, et al., Neurology 1992, 42, 631-9. -   28. K. P. Riley, D. A. Snowdon, and W. R. Markesbery, Ann Neurol     2002, 51, 567-77. -   29.1. Alafuzoff, et al., Acta Neuropathol (Berl) 1987, 74, 209-25. -   30. C. X. Gong, et al., J Neural Transm 2005, 112, 813-38. -   31. K. Iqbal, et al., J Neural Transm Suppl 2002, 309-19. -   32. K. Iqbal, et al., J Mol Neurosci 2003, 20, 425-9. -   33. W. Noble, et al., Proc Natl Acad Sci USA 2005, 102, 6990-5. -   34. S. Le Cone, et al., Proc Nall Acad Sci USA 2006, 103, 9673-8. -   35. S. J. Liu, et al., J Biol Chem 2004, 279, 50078-88. -   36. G. Li, H. Yin, and J. Kuret, J Biol Chem 2004, 279, 15938-45. -   37. T. Y. Chou, G. W. Hart, and C. V. Dang, J Biol Chem 1995, 270,     18961-5. -   38. X. Cheng, G. W. Hart, J Biol Chem 2001, 276, 10570-5. -   39. X. Cheng, et al., Biochemistry 2000, 39, 11609-20. -   40. L. S. Griffith, B. Schmitz, Eur J Biochem 1999, 262, 824-31. -   41. K. Kamemura, G. W. Hart, Prog Nucleic Acid Res Mol Biol 2003,     73, 107-36. -   42. L. Wells, et al., J Biol Chem 2004, 279, 38466-70. -   43. L. Bertram, et al., Science 2000, 290, 2302-3. -   44. S. Hoyer, et al., Journal of Neural Transmission 1998, 105,     423-438. -   45. C. X. Gong, et al., Journal of Alzheimers Disease 2006, 9, 1-12. -   46. W. J. Jagust, et al., Journal of Cerebral Blood Flow and     Metabolism 1991, 11, 323-330. -   47. S. Hoyer, Experimental Gerontology 2000, 35, 1363-1372. -   48. S. Hoyer, in Frontiers in Clinical Neuroscience:     Neurodegeneration and Neuroprotection, Vol. 541, 2004, 135-152. -   49. R. N. Kalaria, S. I. Harik, Journal of Neurochemistry 1989, 53,     1083-1088. -   50.1. A. Simpson, et al., Annals of Neurology 1994, 35, 546-551. -   51. S. M. de la Monte, J. R. Wands, Journal of Alzheimers Disease     2005, 7, 45-61. -   52. X. W. Zhu, G. Perry, and M. A. Smith, Journal of Alzheimers     Disease 2005, 7, 81-84. -   53. J. C. de la Tone, Neurological Research 2004, 26, 517-524. -   54. S. Marshall, W. T. Garvey, and R. R. Traxinger, Faseb J 1991, 5,     3031-6. -   55. S. P. Iyer, Y. Akimoto, and G. W. Hart, J Biol Chem 2003, 278,     5399-409. -   56. K. Brickley, et al., J Biol Chem 2005, 280, 14723-32. -   57. S. Knapp, C. H. Yang, and T. Haimowitz, Tetrahedron Letters     2002, 43, 7101-7104. -   58. S. P. Iyer, G. W. Hart, J Biol Chem 2003, 278, 24608-16. -   59. M. Jinek, et al., Nat Struct Mol Biol 2004, 11, 1001-7. -   60. K Kamemura, et al., J Biol Chem 2002, 277, 19229-35. -   61. Y. Deng, et al., FASEB J. 2007, fj.07-8309com. -   62. L. F. Lau, et al., Curr Top Med Chem 2002, 2, 395-415. -   63. M. P. Mazanetz, P. M. Fischer, Nature Reviews Drug Discovery     2007, 6, 464-479. -   64. S. A. Yuzwa, et al., Nat Chem Biol 2008, 4, 483-490. -   65. P. Bounelis, et al., Shock 2004, 21 170 Suppl. 2, 58-58. -   66. N. Fulop, et al., Circulation Research 2005, 97, E28-E28. -   67. J. Liu, R. B. Marchase, and J. C. Chatham, Faseb Journal 2006,     20, A317-A317. -   68. R. Marchase, et al., PCT Int. Appl. WO 2006016904 2006. -   69. N. Fulop, et al., Journal of Molecular and Cellular Cardiology     2004, 37, 286-287. -   70. N. Fulop, et al., Faseb Journal 2005, 19, A689-A690. -   71. J. Liu, R. B. Marchase, and J. C. Chatham, Journal of Molecular     and Cellular Cardiology 2007, 42, 177-185. -   72. L. G. Not, et al., Faseb Journal 2006, 20, A1471-A1471. -   73. S. L. Yang, et al., Shock 2006, 25, 600-607. -   74. L. Y. Zou, et al., Faseb Journal 2005, 19, A1224-A1224. -   75. R. B. Marchase, et al., Circulation 2004, 110, 1099-1099. -   76. J. Liu, et al., Journal of Molecular and Cellular Cardiology     2006, 40, 303-312. -   77. J. Liu, J. C. Chatham, and R. B. Marchase, Faseb Journal 2005,     19, A691-A691. -   78. T. Nagy, et al., American Journal of Physiology-Cell Physiology     2006, 290, C57-C65. -   79. N. Fulop, R. B. Marchase, and J. C. Chatham, Cardiovascular     Research 2007, 73, 288-297. -   80. T. Lefebvre, et al., Expert Review of Proteomics 2005, 2,     265-275. -   81. B. Henrissat, A. Bairoch, Biochem J 1993, 293 (Pt 3), 781-8. -   82. B. Henrissat, A. Bairoch, Biochem J 1996, 316 (Pt 2), 695-6. -   83. L. Wells, K. Vosseller, and G. W. Hart, Science 2001, 291,     2376-8. -   84. J. A. Hanover, FASEB J2001, 15, 1865-76. -   85. D. A. McClain, et al., Proc Natl Acad Sci USA 2002, 99, 10695-9. -   86. P. J. Yao, P. D. Coleman, J Neurosci 1998, 18, 2399-411. -   87. W. H. Yang, et al., Nature Cell Biology 2006, 8, 1074-U53. -   88. B. Triggs-Raine, D. J. Mahuran, and R. A. Gravel, Adv Genet.     2001, 44, 199-224. -   89. D. Zhou, et al., Science 2004, 1786-89. -   90. G. Legler, et al., Biochim Biophys Acta 1991, 1080, 89-95. -   91. M. Horsch, et al., Eur J Biochem 1991, 197, 815-8. -   92. J. Liu, et al., Chem Biol 2001, 8, 701-11. -   93. S. Knapp, et al., J. Am. Chem. Soc. 1996, 118, 6804-6805. -   94. V. H. Lillelund, et al., Chem Rev 2002, 102, 515-53. -   95. R. J. Konrad, et al., Biochem J2001, 356, 31-41. -   96. K. Liu, et al., J Neurochem 2004, 89, 1044-55. -   97. G. Parker, et al., J Biol Chem 2004, 279, 20636-42. -   98. E. B. Arias, J. Kim, and G. D. Cartee, Diabetes 2004, 53,     921-30. -   99. A. Junod, et al., Proc Soc Exp Biol Med 1967, 126, 201-5. -   100. R. A. Bennett, A. E. Pegg, Cancer Res 1981, 41, 2786-90. -   101. K. D. Kroncke, et al., Biol Chem Hoppe Seyler 1995, 376,     179-85. -   102. H. Yamamoto, Y. Uchigata, and H. Okamoto, Nature 1981, 294,     284-6. -   103. K. Yamada, et al., Diabetes 1982, 31, 749-53. -   104. V. Burkart, et al., Nat Med 1999, 5, 314-9. -   105. M. D. Roos, et al., Proc Assoc Am Physicians 1998, 110, 422-32. -   106. Y. Gao, G. J. Parker, and G. W. Hart, Arch Biochem Biophys     2000, 383, 296-302. -   107. R. Okuyama, M. Yachi, Biochem Biophys Res Commun 2001, 287,     366-71. -   108. N. E. Zachara, et al., J Biol Chem 2004, 279, 30133-42. -   109. J. A. Hanover, et al., Arch Biochem Biophys 1999, 362, 38-45. -   110. K. Liu, et al., Mol Cell Endocrinol 2002, 194, 135-46. -   111. M. S. Macauley, et al., J Biol Chem 2005, 280, 25313-22. -   112. B. L. Mark, et al., J Biol Chem 2001, 276, 10330-7. -   113. R. S. Haltiwanger, K. Grove, and G. A. Philipsberg, J Biol Chem     1998, 273, 3611-7. -   114. D. J. Miller, X. Gong, and B. D. Shur, Development 1993, 118,     1279-89. -   115. L. Y. Zou, et al., Shock 2007, 27, 402-408. -   116. J. B. Huang, A. J. Clark, and H. R. Petty, Cellular Immunology     2007, 245, 1-6. -   117. N. E. Zachara, et al., Abstract 418 in Joint Meeting of the     Society for Glycobiology and the Japanese Society of Carbohydrate     Research. Honolulu, Hi., 2004. -   118. L. Y. Zou, et al., Faseb Journal 2006, 20, A1471-A1471. -   119. V. Champattanachai, R. B. Marchase, and J. C. Chatham, American     Journal of Physiology-Cell Physiology 2007, 292, C178-C187. -   120. V. Champattanachai, R. B. Marchase, and J. C. Chatham, American     Journal of Physiology-Cell Physiology 2008, 294, C1509-C1520. -   121.1. Khlistunova, et al., Current Alzheimer Research 2007, 4,     544-546. -   122. P. Friedhoff, et al., Biochemistry 1998, 37, 10223-10230. -   123. M. Pickhardt, et al., Journal of Biological Chemistry 2005,     280, 3628-3635. 

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:

wherein X is O or S; R¹ and R² are H, or R¹ is H and R² is F, or R¹ is F and R² is H, or R¹ is OR⁵ and R² is H, or R¹ is H and R² is OR⁵; R³ is OR⁵ and R⁴ is H, or R³ is H and R⁴ is OR⁵; R⁶ is H, F, or OR⁵; each R⁵ is independently H or C₁₋₆ acyl; each R⁷ is independently H or F; and each R⁸ is independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy are optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups are connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, wherein when R⁶ is OR⁵, then each R⁷ is H; and wherein when R¹ is OR⁵, then R⁶ is H or F; and wherein when R⁶ is OR⁵, then R¹ is H or F.
 2. The compound of claim 1 wherein: R¹ and R² are H, or R¹ is H and R² is F, or R¹ is F and R² is H, or R¹ is OH and R² is H, or R¹ is H and R² is OH; R³ is H; R⁴ is OH; R⁶ is H or OH; and each R⁸ is independently selected from the group consisting of: H, CH₃, and CH₂CH₃, or NR⁸ ₂ is azetidin-1-yl, wherein when R⁶ is OH, then each R⁷ is H; and wherein when R¹ is OH, then R⁶ is H; and wherein when R⁶ is OH, then R¹ is H or F.
 3. The compound of claim 1 wherein at least one of R¹, R², R⁶, and R⁷ is F.
 4. A compound of Formula (Ia) or a pharmaceutically acceptable salt thereof:

wherein R¹ and R² are H and R⁶ is F; or R¹ is H and R² is F and R⁶ is H, F, or OR⁵; or R¹ is F and R² is H and R⁶ is H, F or OR⁵; or R¹ is OR⁵ and R² is H and R⁶ is F; or R¹ is H and R² is OR⁵ and R⁶ is F; each R⁵ is independently H or C₁₋₆ acyl; each R⁷ is independently H or F; and each R⁸ is independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy are optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups are connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl; wherein when R⁶ is OR⁵, then each R⁷ is H.
 5. (canceled)
 6. The compound of claim 1 wherein the compound is selected from the following group: (3aR,4R,5R,6S,7aS)-2-(ethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(fluoromethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; rac-(3aR,4R,5R,6S,7aS)-2-(ethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-2-(dimethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(dimethylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(ethylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aS,4S,5R,6R,7aS)-2-(azetidin-1-yl)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6R,7aS)-2-(dimethylamino)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6R,7aS)-2-(ethylamino)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-4-fluoro-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5S,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4S,5S,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aS,4R,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4R,5S,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5S,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,5S,6R,7aS)-2-(azetidin-1-yl)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,5R,6R,7aS)-2-(azetidin-1-yl)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-methyl-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4S,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazol-5-ol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazole-4,5-diol; or a pharmaceutically acceptable salt of any of the foregoing compounds.
 7. The compound of claim 1 wherein the compound is a prodrug.
 8. The compound of claim 1 wherein the compound selectively inhibits an O-glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase), selectively binds an O-GlcNAcase, selectively inhibits the cleavage of 2-acetamido-2-deoxy-β-D-glucopyranoside (O-GlcNAc), or does not substantially inhibit a mammalian β-hexosaminidase. 9-10. (canceled)
 11. The compound of claim 8 wherein the O-GlcNAcase is a mammalian O-GlcNAcase.
 12. (canceled)
 13. A pharmaceutical composition comprising the compound of claim 4, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
 14. A method of selectively inhibiting an O-GlcNAcase or of elevating the level of O-GlcNAc or of treating a condition that is modulated by an O-GlcNAcase in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

wherein X is O or S; R¹ and R² are H, or R¹ is H and R² is F, or R¹ is F and R² is H, or R¹ is OR⁵ and R² is H, or R¹ is H and R² is OR⁵; R³ is OR⁵ and R⁴ is H, or R³ is H and R⁴ is OR⁵; R⁶ is H, F, or OR⁵; each R⁵ is independently H or C₁₋₆ acyl; each R⁷ is independently H or F; and each R⁸ is independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy are optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups are connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, wherein when R⁶ is OR⁵, then each R⁷ is H; and wherein when R¹ is OR⁵, then R⁶ is H or F; and wherein when R⁶ is OR⁵, then R¹ is H or F. 15-16. (canceled)
 17. The method of claim 14 wherein the condition is selected from one or more of the group consisting of an inflammatory disease, an allergy, asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias, delayed-type hypersensitivity, atherosclerosis, interstitial lung disease (ILD), idiopathic pulmonary fibrosis, ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis, systemic anaphylaxis or hypersensitivity response, drug allergy, insect sting allergy, autoimmune disease, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, Guillain-Barré syndrome, systemic lupus erythematosus, myastenia gravis, glomerulonephritis, autoimmune thyroiditis, graft rejection, allograft rejection, graft-versus-host disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, spondyloarthropathy, scleroderma, psoriasis, T-cell mediated psoriasis, inflammatory dermatosis, dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria, vasculitis, necrotizing, cutaneous, and hypersensitivity vasculitis, eosinphilic myotis, eosiniphilic fasciitis, solid organ transplant rejection, heart transplant rejection, lung transplant rejection, liver transplant rejection, kidney transplant rejection, pancreas transplant rejection, kidney allograft, lung allograft, epilepsy, pain, fibromyalgia, stroke, neuroprotection.
 18. A method of treating a condition selected from the group consisting of a neurodegenerative disease, a tauopathy, cancer and stress, in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

X is O or S; R¹ and R² are H, or R¹ is H and R² is F, or R¹ is F and R² is H, or R¹ is OR⁵ and R² is H, or R¹ is H and R² is OR⁵; R³ is OR⁵ and R⁴ is H, or R³ is H and R⁴ is OR⁵; R⁶ is H, F, or OR⁵; each R⁵ is independently H or C₁₋₆ acyl; each R⁷ is independently H or F; and each R⁸ is independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy are optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups are connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, wherein when R⁶ is OR⁵, then each R⁷ is H; and wherein when R¹ is OR⁵, then R⁶ is H or F; and wherein when R⁶ is OR⁵, then R¹ is H or F.
 19. The method of claim 18 wherein the condition is selected from one or more of the group consisting of Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Corticobasal degeneration (CBD), Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Multiple system atrophy, Myotonic dystrophy, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Pick's disease (PiD), Post-encephalitic parkinsonism (PEP), Prion diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive supercortical gliosis, Progressive supranuclear palsy (PSP), Richardson's syndrome, Subacute sclerosing panencephalitis, Tangle-only dementia, Huntington's disease, Parkinson's disease, Schizophrenia, Mild Cognitive Impairment (MCI), Neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), or Glaucoma.
 20. The method of claim 18 wherein the stress is a cardiac disorder.
 21. The method of claim 20 wherein the cardiac disorder is selected from one or more of the group consisting of ischemia; hemorrhage; hypovolemic shock; myocardial infarction; an interventional cardiology procedure; cardiac bypass surgery; fibrinolytic therapy; angioplasty; and stent placement.
 22. The method of claim 18 wherein the compound is selected from the following group: (3aR,4R,5R,6S,7aS)-2-(ethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(fluoromethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; rac-(3aR,4R,5R,6S,7aS)-2-(ethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-2-(dimethylamino)-6-(fluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(dimethylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(ethylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aS,4S,5R,6R,7aS)-2-(azetidin-1-yl)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6R,7aS)-2-(dimethylamino)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6R,7aS)-2-(ethylamino)-4-fluoro-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6S,7aS)-6-(difluoromethyl)-4-fluoro-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-4-fluoro-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,4S,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4R,5S,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4S,5S,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aS,4R,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4R,5S,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aS,4S,5S,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,5S,6R,7aS)-2-(azetidin-1-yl)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,5R,6R,7aS)-2-(azetidin-1-yl)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazol-5-ol; (3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-methyl-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol; (3aR,4S,5R,6R,7aS)-4-fluoro-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazol-5-ol; (3aR,4R,5R,6S,7aS)-6-(difluoromethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazole-4,5-diol; or a pharmaceutically acceptable salt of any of the foregoing compounds.
 23. The method of claim 18 wherein said administering increases the level of O-GlcNAc in the subject.
 24. The method of claim 18 wherein the subject is a human. 25-26. (canceled)
 27. A method for screening for a selective inhibitor of an O-GlcNAcase, the method comprising: a) contacting a first sample with a test compound; b) contacting a second sample with a compound of Formula (I)

wherein X is O or S; R¹ and R² are H, or R¹ is H and R² is F, or R¹ is F and R² is H, or R¹ is OR⁵ and R² is H, or R¹ is H and R² is OR⁵; R³ is OR⁵ and R⁴ is H, or R³ is H and R⁴ is OR⁵; R⁶ is H, F, or OR⁵; each R⁵ is independently H or C₁₋₆ acyl; each R⁷ is independently H or F; and each R⁸ is independently selected from the group consisting of: H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, or C₁₋₆ alkoxy are optionally substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, or the two R⁸ groups are connected together with the nitrogen atom to which they are attached to form a ring, said ring optionally independently substituted from one up to the maximum number of substituents with one or more of fluoro, OH, or methyl, wherein when R⁶ is OR⁵, then each R⁷ is H; and wherein when R¹ is OR⁵, then R⁶ is H or F; and wherein when R⁶ is OR⁵, then R¹ is H or F; c) determining the level of inhibition of the O-GlcNAcase in the first and second samples, wherein the test compound is a selective inhibitor of a O-GlcNAcase if the test compound exhibits the same or greater inhibition of the O-GlcNAcase when compared to the compound of Formula (I).
 28. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. 